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Individual variability in immune responses to vaccination can result in vaccinated individuals who 
fail to develop protective immunity. These “vaccine low-responders” remain at risk for infection 
and compromise the protection achieved through herd immunity. Biomarkers of vaccine 
unresponsiveness could enable rapid identification of susceptible low-responders while discerning 
mechanisms of vaccine-induced immune responses. To investigate biomarkers of vaccine 
unresponsiveness, piglets (n=117) were vaccinated with a commercial Mycoplasma 
hyopneumoniae bacterin, and vaccine-induced serum IgG titers were quantified 35 days following 
vaccination. High (HR) and low (LR) vaccine responders within the 80th and 20th percentile of 
serum IgG titers were stratified, respectively, and split into discovery (n=12) and validation (n=8) 
cohorts. Within the discovery cohort, kinome analysis conducted on peripheral blood mononuclear 
cells collected from HR and LR revealed multiple differential phosphorylation events before and 
6-days following vaccination. Differential phosphorylation events before vaccination were 
enriched in cytokine signaling pathways, a result supported by the quantification of higher plasma 
interferon-gamma (IFNγ) and interleukin-1beta (IL-1β) in LR compared to HR before vaccination. 
Additionally, LR had lower birth weight than HR, thus establishing significant associations 
between vaccine responsiveness and kinase signaling, plasma cytokines, and birth weight. 
Analysis of the validation cohort verified the differential phosphorylation events identified within 
the discovery cohort, but there were no differences in birth weight or plasma cytokines between 
LR and HR. In a second trial, piglets (n=67) from a different facility were vaccinated with the 
same Mycoplasma hyopneumoniae bacterin to further evaluate plasma cytokines and birth weight 
as biomarkers of vaccine unresponsiveness. Piglets in the second trial all seroconverted, and serum 
IgG titers varied less than the first trial. While the second trial found no associations between 
vaccine unresponsiveness and either birth weight or plasma cytokines, it revealed piglets had age- 
and litter-dependent differences in plasma IFNγ and IL-1β concentrations within the first 2-months 
of life. Collectively, these data suggest that though plasma cytokines or birth weight can be 
associated with vaccine unresponsiveness, their temporal and individual variability can make them 
inconsistent biomarkers. Phosphorylation biomarkers offered consistent discrimination of HR and 
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1. INTRODUCTION 1 
 2 
1.1 Vaccination and Disease Prevention 3 
Vaccination is one of the most effective and economical means of protecting humans and 4 
animals against infectious diseases. Vaccination aims to induce an immune response within the 5 
individual and establish immunological memory against a molecular fragment that mimics the 6 
pathogen (Zepp, 2016). This preemptive development of vaccine-specific immunity typically 7 
allows the individual to mount an immune response to the live-infectious agent (Pollard and Bijker, 8 
2021). However, biological variability among individuals can result in inconsistent vaccine 9 
immunogenicity, particularly within populations that are heterogeneous with respect to genetics, 10 
age, and health status. Individuals may develop weak vaccine-induced immune responses resulting 11 
in the immune system being incapable of preventing or minimizing infection by the vaccine-12 
associated pathogen. Therefore, individuals who are incapable of responding (termed “non-13 
responders”) or respond insufficiently (termed “low-responders”) to the vaccine are a potential 14 
detriment to the health of the population and require appropriate management. 15 
1.1.1 Individual Variability in Vaccine Responses 16 
Individual variation in vaccine responses is a natural occurrence that can result in low 17 
vaccine responders within a population. This phenomenon has been observed for multiple vaccine 18 
regimens in a range of species. For example, 5-10% of individuals vaccinated against hepatitis B 19 
virus (HBV) failed to develop protective levels (anti-HBs>10 mIU) of anti-HBV antibody 20 
(Averhoff et al., 1998; Poland and Jacobson, 2004; Walayat et al., 2015). Vaccines against the 21 
influenza virus can be an effective means of disease control, yet antibody responses following 22 
influenza virus vaccination consistently vary among populations, independent of influenza 23 
strain/season (Keitel et al., 2006; Levine et al., 2016; Nakaya et al., 2015). Within animal health, 24 
piglets vaccinated against tetanus toxoid can exhibit a range of seropositive and seronegative 25 
antibody responses 28-days following vaccination, suggesting inconsistent levels of protection 26 
(Adler et al., 2015). Recently, pigs vaccinated with a commercial Mycoplasma hyopneumoniae 27 
(M. hyopneumoniae) bacterin had highly variable M. hyopneumoniae-specific antibody responses, 28 
with only 80% of pigs having persistent antibody responses 118-days post-vaccination (Blanc et 29 




commercial and experimental foot-and-mouth-disease virus (FMDV) vaccines (Braun et al., 2018; 31 
Jouneau et al., 2020; Knight-Jones et al., 2015). While factors influencing the magnitude of 32 
vaccine responses are explored later (Section 1.3), these previous studies demonstrate that a 33 
variety of vaccines used in both humans and animals can result in individuals classified as vaccine 34 
low-responders. 35 
1.1.2 Protection through Herd Immunity 36 
The protection afforded by vaccination is achieved at the level of the individual and the 37 
population. For individuals, vaccination programs usually prioritize either reducing infection 38 
susceptibility or promoting pathogen clearance, while from the population perspective, the priority 39 
is to reduce the incidence of exposure and limit infections (Rose and Andraud, 2017; Smith, 2010). 40 
A vaccine's effectiveness depends on multiple factors, including the pathogen transmission 41 
potential, vaccine coverage, and vaccine efficacy. If the transmission potential of the pathogen is 42 
high, the vaccine coverage must compensate to establish protection in the population. The basic 43 
reproduction number of a pathogen (R0) is the average number of secondary infections a single 44 
infectious individual infects within a susceptible population. R0 is directly proportional to the 45 
number of protected individuals needed to establish population-wide protection, known as herd 46 
immunity (Fine et al., 2011; Smith, 2010). Pathogens with a high R0, such as measles virus (R0 ~ 47 
12 to 18), require a higher vaccine coverage of the population than other pathogens with a lower 48 
R0, such as influenza virus (R0 ~ 1 to 2) (Biggerstaff et al., 2014; Guerra et al., 2017). The R0 is 49 
highly dependent on biological and sociodemographical factors but can be estimated using “P = 50 
1-(1/R0)”, where P = the proportion of the population to vaccinate to stop transmission (Guerra et 51 
al., 2017; Smith, 2010). So, when a sufficient proportion of the population has been vaccinated 52 
against the pathogen, pathogen transmission is hindered and reduces the probability of 53 
encountering unvaccinated and susceptible individuals (Rose and Andraud, 2017).  54 
Vaccine efficacy, the ability to reduce disease incidence, relies on vaccine 55 
immunogenicity, the vaccine's ability to trigger an immune response (Mahanty et al., 2015; Smith, 56 
2010). Therefore, factors that compromise vaccine immunogenicity inevitably reduce vaccines 57 
efficacy by promoting the development of vaccine non-responders (Weinberg and Szilagyi, 2010). 58 
In addition, vaccine non-responders challenge the achievement of herd immunity, requiring a 59 




non-responders impair protection of individuals, but they also compromise efforts to achieve herd 61 
immunity and should be identified and managed accordingly. 62 
1.1.3 Biomarkers of Vaccine Responses 63 
Identifying vaccine non-responders/low-responders usually requires quantifying surrogate 64 
metrics of vaccine outcomes, such as antigen-specific antibody titers or T-cell responses, in the 65 
weeks following immunization (Plotkin, 2001). This approach to quantifying vaccine responses 66 
has several practical limitations. First, there is a window of opportunity between vaccination and 67 
quantification of vaccine outcomes when pathogens may infect and be transmitted by non-68 
responders within the population. Second, quantifying these surrogate metrics requires additional 69 
time and economic cost to the health care system or livestock producer. This problem creates a 70 
need for more rapid and inexpensive identification of non-responders. Early identification of 71 
vaccine non-responders through biological markers (termed “biomarkers”) that reduce the time of 72 
identification and/or the cost of testing could provide a valuable tool for improving individual and 73 
population health. The discovery of biomarkers capable of predicting future vaccine responses 74 
could allow immediate identification of vaccine non-responders and facilitate strategic 75 
management decisions, such as revaccination, physical isolation, or, in the livestock industry, 76 
culling or genetic selection of individual animals (te Beest et al., 2011; Knight-Jones et al., 2015; 77 
Mallard et al., 2015). As well, biomarkers providing a molecular basis of vaccine unresponsiveness 78 
could be utilized to improve vaccine delivery strategies to minimize the frequency of vaccine non-79 
responders (Pulendran et al., 2010). Research into understanding the molecular events within the 80 
host immune system before and after vaccination may prove fruitful in discovering possible 81 
biomarkers of vaccine responsiveness.  82 
1.2 Immune Responses to Vaccination 83 
The primary objective of vaccination is to induce an immune response against a specific 84 
pathogen that can prevent clinical symptoms of infection (Zepp, 2016). A variety of pathogen 85 
components can act as vaccine antigens, including biomolecular components of the pathogen (e.g. 86 
protein subunits, peptides, toxins, polysaccharides, nucleic acids) or an inactivated/killed version 87 
of the pathogen itself. Alternatively, attenuated pathogens can be generated by removing the 88 




system can generate immunity (Pollard and Bijker, 2021). In either case, vaccination prepares the 90 
immune system to detect, mediate, and respond against a future attack by the pathogen. 91 
1.2.1 The Innate Immune Response 92 
The innate immune system represents the initial line of defense against invading pathogens 93 
and consists of phagocytic cells, protein complement, and physical barriers. Innate responses occur 94 
within minutes to hours of infections and are hallmarked by being relatively nonspecific and 95 
lacking immunological memory to recognize recurring infectious agents (Coffman et al., 2010). 96 
The breadth of detection by the innate immune system is derived from its ability to recognize a 97 
spectrum of bacteria, viruses, parasites, or tissue damage. Detecting infectious agents is facilitated 98 
by pathogen recognition receptors (PRRs) on host cells, including phagocytic dendritic cells. PRRs 99 
like Toll-like receptors (TLRs) recognize and bind pathogens through evolutionary distinct but 100 
highly conserved molecules called pathogen-associated molecular patterns (Pulendran and 101 
Ahmed, 2011; Rosadini and Kagan, 2017). PRRs bind a range of pathogen-associated molecular 102 
patterns (e.g. lipopolysaccharide, viral nucleic acids) to activate signal transduction events. PRR 103 
activation results in the expression of genes encoding proteins involved in defensive host activities 104 
including pro-inflammatory cytokine release, complement cascades, pathogen opsonization, and 105 
the recruitment of phagocytes (Mogensen, 2009; Takeda and Akira, 2004). These processes 106 
promote pathogen clearance, minimize damages to the host, and, importantly for vaccination, 107 
initiate antigen-specific responses. 108 
A critical cell type for transitioning from an innate immune response into an adaptive 109 
immune response are the dendritic cells. The dendritic cells sense, engulf, and lyse pathogens to 110 
present antigenic fragments on their extracellular surface (Pulendran and Ahmed, 2006). This 111 
stimulation of dendritic cells differentiates the cell into an antigen-presenting cell, where cytokine 112 
signals coordinate the migration of activated dendritic cell to the draining lymph nodes (Iwasaki 113 
and Medzhitov, 2004). Here, antigen-presentation cells prime and direct T-cell differentiation by 114 
presenting antigenic fragments on major histocompatibility complex (MHC), along with other 115 
costimulatory molecules, to naive T-lymphocytes (Iwasaki and Medzhitov, 2004; Reis e Sousa, 116 
2004). Vaccines must stimulate specific T- and B-lymphocyte responses to establish 117 




1.2.2 The Adaptive Immune Response  119 
Compared to the innate immune response, the adaptive immune response develops more 120 
slowly, is pathogen-specific, and leads to immunological memory. Pathogens have evolved 121 
mechanisms to evade innate immune responses, so establishing an adaptive immune response 122 
enables the immune system to recognize pathogen-specific antigens (Janeway et al., 2001). T-123 
lymphocytes deliberate effector and regulatory functions, while B-lymphocytes primarily mediate 124 
antigen-specific antibody responses (Zepp, 2016). T- and B-lymphocytes express clonal antigen 125 
recognition receptors, called T-cell receptors and B-cell receptors, respectively, that bind 126 
specifically to antigen peptides and lead to T- and B-lymphocyte activation and differentiation 127 
(Janeway et al., 2001; Pulendran and Ahmed, 2011). Recognizing the roles of lymphocytes and 128 
their activities within the vaccine-induced immune response may be critical for distinguishing 129 
responders from non-responders. 130 
1.2.2.1 T-lymphocytes and Cellular Responses 131 
T-cells have many functions that largely depend on their distinct functional  subset (Kumar 132 
et al., 2018). Nucleated cells intracellularly infected with a pathogen communicate their infection 133 
by processing, loading, and presenting antigenic fragments of the pathogen onto the cell surface 134 
through MHC class 1 proteins. MHC-I resides on the surface of all nucleated cells and bear both 135 
endogenous degradation of self and foreign antigens (Hewitt, 2003). T-cells bearing the surface 136 
protein CD8 (CD8+ T-cells) recognize foreign antigens through surface T-cell receptors and bind 137 
the antigen-MHC-I complex, leading to a cytotoxic response and killing infected cells with 138 
cytotoxic factors. Conversely, exogenously-derived foreign antigens are presented by antigen-139 
presenting cells on MHC Class II receptors which are recognized by T-cell receptors on T-cells 140 
bearing the surface protein CD4 (CD4+ T-cells) (Hewitt, 2003). Analyses of vaccine responders 141 
to HBV vaccination found recessive haplotypes of MHC-II human histocompatibility leukocyte 142 
antigen in non-responders, suggesting that there are associations between mutations in the MHC-143 
II presentation system and impaired vaccine responses (Alper et al., 1998; Kruskall et al., 1992). 144 
T-cell receptor stimulation, combined with co-stimulatory and cytokine signals, commits the 145 
CD4+ T-cell into one of many helper T-cell subsets. Helper T-cells have many supportive 146 
functions in activating innate immune cells, promoting T-cell differentiation, promoting antibody 147 




2001). Current vaccines must optimize the coordination among the vaccine antigen, helper T-cells, 149 
and B-cells to induce protective vaccine-specific immune responses. 150 
1.2.2.2 B-lymphocytes and Antibody Responses 151 
B-lymphocytes, are the primary cell of the humoral response due to their ability to generate 152 
and secrete antibodies specific to an antigenic fragment (Alberts et al., 2002). Antigen-specific 153 
antibody generation is initiated when whole proteins or antigenic fragments bind the B-cell 154 
receptor. Antigens can bind B-cell receptors either with (T-cell-dependent) or without (T-cell-155 
independent) co-stimulation from antigen-specific T-cells recognizing the same antigen, yet T-156 
cell-independent binding typically generates a weaker response and lacks memory (Pollard and 157 
Bijker, 2021; Pulendran and Ahmed, 2006).  T-cell-dependent activation leads to downstream 158 
signaling effectors that result in cytoskeletal rearrangement and the maturation and differentiation 159 
of the antigen-specific B-lymphocyte (Crotty, 2015; Janeway et al., 2001; Li et al., 2019). 160 
Activated B-lymphocytes produce antigen-specific antibody isotypes like immunoglobulin G 161 
(IgG) or IgA with high affinity and differentiate into antibody-producing plasma cells or memory 162 
B-cells. Memory B-cells differentiate with the help of CD4+ T-cells to provide rapid antibody 163 
responses following antigen re-exposure, while plasma cells continuously secrete antibodies into 164 
the circulation (Alberts et al., 2002; Pollard and Bijker, 2021; Zepp, 2016). However, the 165 
generation of antigen-specific antibodies may not protect against infections, as observed with 166 
intracellular pathogens like Mycobacterium tuberculosis or HIV (Siegrist, 2018). Therefore, 167 
vaccine optimization requires recognizing the antigen-specific effectors needed for protection 168 
against a given pathogen (Pulendran and Ahmed, 2011). 169 
Establishing innate and adaptive immune responses requires highly integrated cellular 170 
communication through various signaling cascades to achieve an effective, antigen-specific 171 
response. As a result, modulating the expression and activity of receptors, transcription factors, 172 
signaling molecules, or changes in cell frequencies can profoundly influence the immune response 173 
to vaccines. These modulations are known to be driven by vaccine, host, environmental, and 174 
developmental factors. 175 
1.3 Factors affecting Vaccine Responses 176 
Numerous vaccine and host factors modulate the immune response within both the innate 177 




related to the vaccine, such as antigen optimization, adjuvant selection, vaccine type, and 179 
administration method. In addition, the individual variation in vaccine-induced immune responses 180 
is primarily attributed to heterogeneity within a population determined by genetic differences, prior 181 
environmental exposures, perinatal factors, nutrition, and behavior, to name a few (Zimmermann 182 
and Curtis, 2019). Vaccination must overcome these factors to elicit an antigen-specific immune 183 
response. 184 
1.3.1 Vaccine-Dependent Factors 185 
1.3.1.1 Vaccine Adjuvants 186 
Adjuvants, such as mineral salts, oil and water emulsions, PRR ligands, and cytokines, 187 
modulate vaccine responses to increase vaccine antigen immunogenicity. Adjuvants enhance 188 
immune responses by multiple mechanisms. This includes stimulating the innate immune system, 189 
forming antigen depots and sustaining the release of the antigen, upregulating cytokines, activating 190 
inflammasomes, recruiting leukocytes to the injection site, or activating antigen-presenting cells 191 
(Awate et al., 2013). For example, AS03, an oil-in-water emulsion, enhances antigen uptake and 192 
antigen presentation by stimulating nuclear factor-κB transcriptional activity and cytokine and 193 
chemokine responses to activate monocytes into antigen-presenting cells at the site of injection 194 
(Coffman et al., 2010; Garçon et al., 2014). AS03 facilitates the activation of CD4+ T-cells to 195 
promote stronger adaptive immune responses in current influenza-virus vaccines (Garçon et al., 196 
2014). Furthermore, adjuvants in a vaccine formulation can strengthen vaccine-induced immune 197 
responses thereby reducing the incidence of vaccine non-responders. Within livestock, sheep 198 
vaccinated against FMDV revealed higher virus neutralization titers when vaccinated with a 199 
vaccine containing a water-in-oil emulsion adjuvant compared to an unadjuvanted vaccine antigen 200 
(Jouneau et al., 2020). In developing novel M. hyopneumoniae vaccines, researchers found that 201 
experimental vaccine formulations differing only in adjuvant selection (various PRR ligands or 202 
squalene-in-water emulsions) led to highly variable vaccine-specific IgG titers, CD4+, and CD8+ 203 
T-cell responses within vaccinated pigs (Matthijs et al., 2019). The selection of different adjuvants 204 
is just one method that allows vaccine manufacturers to modify the immune response required to 205 




1.3.1.2 Vaccine Type and Antigen Selection 207 
Vaccine type, antigen selection, and pathogen strain can also influence vaccine-specific 208 
immune responses. For example, a small cohort of humans vaccinated with trivalent influenza 209 
vaccine had statistically higher hemagglutination inhibition titers than a cohort vaccinated with 210 
live-attenuated influenza virus (Nakaya et al., 2011). Similarly, in a study by Jouneau et al. (2020), 211 
sheep vaccinated with an inactivated FMDV responded with higher post-vaccination virus-212 
neutralization titers over one year than sheep vaccinated with a replication-defective adenovirus 5 213 
vector expressing FMDV capsid proteins. This study suggested there are substantial differences in 214 
vaccine-induced immune responses depending on the vaccine type (Jouneau et al., 2020). As 215 
vaccine immunogenicity relies on the antigen’s ability to trigger the T- and B-cell receptors, 216 
optimal antigen selection is critical for developing vaccines that stimulate immune responses 217 
(Mahanty et al., 2015). Also, diversity in the strain of pathogen used to formulate the vaccine can 218 
impact the vaccine-induced immune response, as evidenced in the development of influenza virus 219 
vaccines that use different strains than the pathogen circulating in the environment  (Keitel et al., 220 
2006; Levine et al., 2016; Maes et al., 2021). Indeed, all aspects of the vaccine, up to and including 221 
administration technique, should be optimized to generate a strong vaccine-induced immune 222 
response (Zhang et al., 2015). Nevertheless, the formulation of the vaccine does not explain why 223 
individuals given the same vaccine can generate highly variable vaccine responses. To further 224 
investigate this phenotype, host factors that influence the immune response need to be considered.  225 
1.3.2 Host-dependent Factors 226 
1.3.2.1 Genetics and Heritability 227 
Genetic factors can partially explain the heterogeneity of vaccine-induced immune 228 
responses in a population. In a meta-analysis by Posteraro et al. (2014), genes involved in antigen 229 
recognition and cytokine responses had single nucleotide polymorphisms (SNPs) that were 230 
associated with vaccine-induced antibody responses following measles virus, HBV, or 231 
meningococcus vaccination.  However, there was not a consistent set of genes common across all 232 
vaccine responses, suggesting individual genetic differences could have vaccine-specific effects 233 
(Posteraro et al., 2014). A high number of genetic associations were found between human 234 
histocompatibility leukocyte antigen gene polymorphisms in humans and their post-vaccination 235 
influenza-specific antibody titers, highlighting the importance of antigen-presentation proteins in 236 




vaccine-specific responses is associated with genetic polymorphisms was observed in 238 
investigations that follow measles virus vaccination. SNPs in the genes coding cell surface 239 
receptors, CD46 and signaling lymphocyte-activation molecule, have been associated with allele-240 
dependent variations in measles-specific antibody responses, while SNPs in TLR coding genes 241 
have been inconsistently associated with measles immunity (Dhiman et al., 2007; Ovsyannikova 242 
et al., 2011, 2014). Dairy cattle classified as either antibody-mediated immune responders or cell-243 
mediated immune responders were genotyped and revealed a high representation of SNPs in 244 
bovine MHC genes, complement protein genes, and cytokines associated with immune 245 
responsiveness (Thompson-Crispi et al., 2014). Altogether, there is strong evidence that gene 246 
polymorphisms in antigen presentation proteins, T-cell recognition proteins, and cytokine 247 
signaling genes are associated with variations in the vaccine response. 248 
Additional evidence suggests that genomic factors contribute to, but cannot fully explain, 249 
the total heterogeneity of vaccine responses. A study by Newport et al. (2004) evaluated the 250 
contributions of genetic and environmental factors on vaccine-induced immune responses using a 251 
cohort of dizygotic and monozygotic twins. Here, the heritability of vaccine-induced antibody 252 
responses was 44-78%, depending on the vaccine antigen (tetanus toxin, diphtheria toxin, oral 253 
poliovirus, and HBV) (Newport et al., 2004). Another large (n=210 pairs) human twin study that 254 
analyzed immune cell subsets and serum protein composition revealed that heritable factors 255 
contributed to <20% of the total variation in 61% of the measured cell populations and 69% of the 256 
measured serum proteins (Brodin et al., 2015). Genome-wide association studies of piglets 257 
vaccinated against M. hyopneumoniae identified multiple SNPs positively correlated to M. 258 
hyopneumoniae-antibody responses. The heritability of M. hyopneumoniae-antibody response in 259 
this population was determined to be between 0.46 and 0.57, further demonstrating that 260 
environmental and non-genetic factors must be determinants of variability in vaccine responses 261 
(Blanc et al., 2021). Finally, not all non-/low-responders are permanently incapable of responding 262 
to vaccines, as demonstrated by a study on human neonates with low (anti-HB titer<100 mIU/mL) 263 
antibody response following hepatitis B vaccination. This study revealed that revaccination of non-264 
responders and low-responders increased antibody titers after additional doses, suggesting vaccine 265 
unresponsiveness can be a temporal phenotype (Han et al., 2012). Thus, vaccine responsiveness is 266 
dynamic, and challenges to the immune system may critically influence the vaccine-induced 267 




1.3.2.2 Inflammation and Immune Activation 269 
Inflammation is a natural host response to pathogens, toxins, and cell damage (Chen et al., 270 
2018). While adjuvants may stimulate an acute inflammatory response to activate innate immunes 271 
cells and recruit cells to the site of danger, a chronic inflammatory condition can be detrimental to 272 
vaccine-induced immune responses by exhausting cytokines and lymphocytes and desensitizing 273 
antigen-presenting cells to PRR stimulation (Alter and Sekaly, 2015; Muyanja et al., 2014; Panda 274 
et al., 2010). This chronic inflammatory phenotype has been partially characterized by greater 275 
circulating inflammatory cytokines and increased immune activation, which contributes to a 276 
negative association with vaccine-induced immune responses (Frasca et al., 2014; Muyanja et al., 277 
2014).  278 
Much of the research relating to inflammation and vaccine unresponsiveness has been done in 279 
the context of aging. Vaccine-specific antibody responses to influenza vaccination consistently 280 
declines with age (Fourati et al., 2016; Lambert et al., 2012; Panda et al., 2010; Poland et al., 281 
2014). Investigations into the cause of this observation have identified a low-grade, chronic 282 
inflammation within older persons (termed “inflammaging”), as well as a reduced T cell repertoire 283 
(Lambert et al., 2012). Frasca et al. (2012) found that while B-cells collected from older (>65 284 
years) persons had baseline higher levels of TNFα expression compared to younger (≤64 years) 285 
persons, the B-cells from older person produced lower TNFα levels in response to 286 
lipopolysaccharide stimulation than the B-cells from younger persons. As well, incubating B-cells 287 
with TNFα before lipopolysaccharide stimulation decreases the expression and secretion of TNFα, 288 
demonstrating there are differences in immune responsiveness between older cells with greater 289 
exposure to pro-inflammatory cytokines and younger cells (Frasca et al., 2012a). Increased 290 
circulating pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNFα) and 291 
interleukin (IL)-6 are observed in older individuals with poor B-cell responses to influenza virus 292 
vaccination compared to younger individuals with more robust B-cell responses (Frasca et al., 293 
2014; Trzonkowski et al., 2003). Poland et al. (2014) reviewed the possible effects of aging on the 294 
vaccine response, citing immunosenescence, diminished innate immunity responses, decreases in 295 
T-cell and B-cell receptor diversity, and dysregulated release of cytokines as significant factors 296 
(Poland et al., 2014). The age-related impairment of vaccine responses provides evidence that the 297 




Similar to aging, body weight, namely, excess adipose (obesity) and low birth weight, are other 299 
phenotypic markers associated with chronic inflammation and vaccine responsiveness. Obesity 300 
has been a risk factor for reduced vaccine responsiveness in humans following multiple 301 
vaccination programs (Eliakim et al., 2006; Painter et al., 2015; Weber, 1985). A common factor 302 
between the obesity and aging phenotype is the increased chronic inflammatory condition, as 303 
demonstrated by greater expression and circulating levels of TNFα, IL-1β, and IL-6 in obese 304 
humans and mice fed a high-fat diet (Frasca et al., 2016; Trayhurn and Wood, 2004). Following 305 
influenza vaccination, mice on a high-fat diet had lower neutralizing antibody titers and fewer 306 
influenza-specific CD8+ T-cells than normal-weight mice (Park et al., 2014). While the 307 
mechanisms by which the inflammatory condition affects vaccine responses are not exact, 308 
researchers have proposed that chronic inflammation can lead to immune cell tolerance, 309 
suboptimal macrophage functions, and impaired cytokine responses (Honce and Schultz-Cherry, 310 
2019; Park et al., 2014). 311 
Body weight at other time points in life, such as birth, may also have negative effects on 312 
vaccine responses. For example, a study of adolescent humans revealed that being small for 313 
gestational age (based on birth weight) resulted in the lowest probability of generating vaccine-314 
specific serum IgG titers to typhoid vaccination (McDade et al., 2001). These individuals with 315 
lower serum IgG titers had greater plasma concentrations of the pro-inflammatory marker, C-316 
reactive protein, than individuals with higher serum IgG (McDade et al., 2011). Thus, 317 
dysregulation of immune function due to variables like age, body weight, and polymorphisms in 318 
cytokine and inflammatory signaling genes appear to contribute to increased circulating 319 
inflammatory signals that might hinder the development of the vaccine-specific immune response. 320 
1.3.2.3 Microbiome and Antibiotic Use 321 
Gut microbiomes contain trillions of bacteria (that outnumber the eukaryotic cells of the 322 
host) and have the propensity to shape host processes, such as metabolism (Turnbaugh et al., 323 
2006), pharmacokinetics (Sousa et al., 2008), and immunity (Belkaid and Hand, 2014). For this 324 
reason, multiple research groups have begun to surmise the microbiome’s role in vaccine-induced 325 
immune responses. Evidence collected by Oh et al. (2014) revealed antibiotic-treated mice had 326 
reduced influenza-specific IgM and IgG following influenza virus vaccination. However, when 327 




TLR5 ligand, flagellin, IgG titers were restored to levels similar to that in mice untreated with 329 
antibiotics. These results support the hypothesis that microbial products can act as natural 330 
adjuvants to enhance host responsiveness against unadjuvanted vaccines (Oh et al., 2014). Further 331 
studies demonstrated that antibiotic treatment of mice at a young age diminished commensal 332 
bacteria and impaired vaccine-specific antibody responses to multiple vaccines. The reduction in 333 
vaccine-specific antibody responses could be reversed by fecal microbiota transfer of commensal 334 
bacteria to antibiotic-treated mice, providing further evidence for an essential role of gut 335 
microflora in modulating host vaccine responses (Lynn et al., 2018). The effect of antibiotic usage 336 
on vaccine responses in pigs vaccinated against M. hyopneumoniae was investigated as well, but 337 
there were no differences in vaccine-specific antibody responses when comparing antibiotic-338 
treated subjects and controls (Munyaka et al., 2019). Remarkably, microbiota analysis in an 339 
independent cohort of pigs vaccinated against M. hyopneumoniae revealed that pigs with the 340 
highest and lowest vaccine-induced antibody responses had differences in operational taxonomical 341 
units belonging to the genus Prevotella on the day of vaccination (Munyaka et al., 2020). Together, 342 
these studies illustrate that specific bacterial species may influence certain immune responses to 343 
vaccination.  344 
Only a few variables that influence vaccine responsiveness have been described here, yet 345 
many others have been studied, including environmental, behavioral, maternal, and nutritional 346 
factors (Zimmermann & Curtis, 2019). Each factor can contribute to variation in an individual’s 347 
cellular function (i.e. gene expression, cell population frequency, immune tolerance) (Brodin et 348 
al., 2015). Given the interactions among these factors, it can be challenging to identify a single 349 
cause for impaired vaccine responses using reductionist approaches. A systems biology approach 350 
may better identify the mechanisms driving vaccine-induced immune responses (Pulendran et al., 351 
2010).  352 
1.4 Systems Biology Analysis of the Vaccine Response 353 
Researchers employed systems biology approaches to elucidate the global molecular 354 
events and cellular responses of vaccine-induced immune responses. Some of the earliest work 355 
done in the field of “systems vaccinology” used global analysis techniques to characterize immune 356 
responses to vaccination with human vaccines (Pulendran et al., 2010). This emerging field aims 357 




generate knowledge behind the phenotype and influence the development of future vaccines 359 
(Wimmers and Pulendran, 2020).  360 
1.4.1 Correlates of Vaccine Outcomes Following Vaccination  361 
Early systems biology applications of vaccine responsiveness identified gene expression 362 
and cellular responses following vaccination. In a cohort of adults vaccinated against Yellow Fever 363 
17D, Gaucher et al. (2008) observed consistent patterns of gene expression, such as the expression 364 
of interferon pathway genes, complement system components, TLR-associated genes, and B-cell 365 
activation genes, at 3- and 7-days post-vaccination. Polychromatic flow cytometry of peripheral 366 
blood mononuclear cells (PBMCs) from vaccinated individuals identified an overall increase in T-367 
cells within 14 days of vaccination, while a cytometric bead assay identified unique PBMC 368 
cytokine responses to Yellow Fever-derived peptides at 60-days post-vaccination. Through 369 
combining transcriptomics, cytometry, and cytokine profiles, researchers obtained a 370 
comprehensive view of the Yellow Fever vaccine response (Gaucher et al., 2008). Querec et al. 371 
(2009) also conducted early research to identify gene networks associated with vaccine 372 
responsiveness following Yellow Fever vaccination. This study observed the expression of genes 373 
involved in complement cascades, T-cell activity, and virus-sensing responses early after 374 
vaccination against the Yellow Fever 17D virus (Querec et al., 2009). A study by Li et al. (2013) 375 
augmented this research by conducting a multi-cohort analysis exploring the gene expression 376 
events in blood leukocytes following vaccination against Yellow Fever 17D virus, influenza virus, 377 
and meningococcus to identify a potential “universal” vaccine response. This study found 378 
distinctive patterns of gene expression corresponding to the particulars of the vaccine, reinforcing 379 
that vaccine factors, such as strain or vaccine type, can influence the associated vaccine-specific 380 
immune responses (Li et al., 2014). Together, these studies demonstrate that systems biology 381 
approaches can identify correlates of various vaccine outcomes early after vaccination. However, 382 
these studies did not answer the question regarding the mechanism(s) underlying the vaccine non-383 
responder phenotype.  384 
1.4.2 Post-vaccination Events in Vaccine Non-Responders  385 
Given the ability of systems biology to describe the transcriptional and cellular changes in 386 
response to successful vaccinations, researchers sought to utilize these approaches to characterize 387 




transcriptomic responses were evaluated before vaccination, and at 3- and 7-days following 389 
influenza virus vaccination. Microarray analysis was conducted on subjects classified as “high” 390 
and “low” responders based on hemagglutination-inhibition antibody titers 28-days following 391 
vaccination using PBMCs collected 0-, 3-, and 7-days post-vaccination. This analysis revealed 392 
differentially expressed genes capable of predicting independent vaccine responders with high 393 
(>85%) accuracy (Nakaya et al., 2011). These results indicated that systems biology approaches 394 
could identify molecular events associated with non-response and be instrumental in predicting 395 
unresponsiveness. Subsequent studies used similar strategies to investigate the differences 396 
between vaccine responders and non-responders following vaccination with influenza virus 397 
(Nakaya et al., 2015; Panda et al., 2010; Zimmermann et al., 2017), HBV (Bartholomeus et al., 398 
2018; Shannon et al., 2020), measles virus (Haralambieva et al., 2018), and M. hyopneumoniae 399 
(Munyaka et al., 2019). As a result, there is a growing body of work determining the gene 400 
expression signatures associated with non-responders following various vaccination programs. 401 
Research into the molecular mechanisms of vaccine unresponsiveness in livestock species 402 
using systems biology technology has been sparse. This is possibly due to curated databases 403 
containing the transcriptomes and proteomes of livestock species being not as well-annotated as 404 
model organisms such as humans and mice (Bick et al., 2019). Translating these technologies to 405 
livestock species such as cattle, pigs, or sheep, can substantiate research programs with large 406 
animal models that are highly comparative to human physiology and health (Facciuolo et al., 2020; 407 
Hein and Griebel, 2003). Transcriptional studies on PBMCs collected from pigs following tetanus 408 
toxoid (Adler et al., 2015) and M. hyopneumoniae vaccination (Munyaka et al., 2019) did not 409 
reveal significant differences in gene expression between high and low vaccine responders either 410 
before or after vaccination. Others have adapted computational analyses designed for humans to 411 
work on other species such as sheep and swine (Braun et al., 2018; Jouneau et al., 2020; Matthijs 412 
et al., 2019). These new computational frameworks were used in sheep vaccinated against FMDV 413 
to identify downregulated T-cell activities and platelet activation in high vaccine responders 414 
compared to low vaccine responders (Jouneau et al. 2020). The computational adaptation for 415 
different species, specifically livestock, has enabled a broader scope of systems vaccinology 416 




1.4.3 Pre-vaccination Events of Vaccine Non-Responders 418 
In contrast to defining gene expression events and frequencies of cell populations that 419 
follow vaccination, few researchers have characterized how the immune environment of the host 420 
at the time of vaccination impacts vaccine-induced immune responses. Pre-vaccination factors 421 
such as genetic predispositions, inflammation, and microbiomes have been examined in isolation, 422 
but systems biology analyses could provide insight into the global host characteristics (i.e. cell 423 
populations and cellular processes) that influence the vaccine-induced immune response. Tsang et 424 
al. (2014) demonstrated that inter-individual differences in gene expression and cell population 425 
frequencies prior to influenza virus vaccination correlated with influenza-specific responses in 426 
humans. Metrics such as pre-vaccination serum IgG titers and subsets of lymphocytes had power 427 
for predicting post-vaccination influenza-specific responses and provided a model for future 428 
predictions (Tsang et al., 2014). A similar analysis found baseline predictors of vaccine 429 
responsiveness to influenza vaccination in elderly adults (60 to 89 years); transcription of 430 
apoptosis-related genes prior to vaccination was positively correlated with strong vaccine-specific 431 
antibody responses. (Furman et al., 2013). In a study of humans vaccinated against HBV, older 432 
individuals with lower HBV-specific antibody responses had multiple differentially expressed 433 
genes involved in inflammation prior to vaccination than younger individuals with high antibody 434 
responses (Fourati et al., 2016). However, transcriptional analysis of pre-vaccination blood 435 
leukocytes has not consistently identified correlates of post-vaccination vaccine responses 436 
(Munyaka et al., 2019). Thus, while an individual’s pre-vaccination immune state might not 437 
always predict their post-vaccination response, it remains a valuable control for describing 438 
individual variation prior to vaccination. 439 
1.4.4 Integrating Omic Analyses 440 
Transcriptional analyses have been a significant component of systems vaccinology 441 
research, yet these studies might not reflect the cell's phenotype. mRNA levels do not always 442 
directly correlate with protein abundance due to mRNA degradation, miRNA silencing, or protein 443 
half-lives, and provide little detail on a protein’s activity (Anderson and Seilhamer, 1997; 444 
Greenbaum et al., 2003; Liu et al., 2016). Proteomic approaches that quantify a protein’s 445 
abundance or characterize a protein’s activity can supplement the current understanding of 446 
vaccine-induced immune responses (Galassie and Link, 2015). For example, mass spectrometry 447 




upregulation of proteins involved in TLR-signaling and JAK-STAT signaling compared to 449 
unvaccinated controls (Lopez et al., 2018). Others have conducted cytokine profiling of human 450 
subjects before and after vaccination to identify correlations between circulating cytokine 451 
concentrations with vaccine-induced immune responses (Fourati et al., 2016; Qiu et al., 2018; 452 
Querec et al., 2009). To discover vaccine responsiveness biomarkers, Furman et al. (2013) used 453 
peptide fragments of the hemagglutinin protein of the influenza virus to detect pre-existing 454 
antibodies against the viral protein. Individuals with lower vaccine-specific antibody responses 455 
had higher pre-existing antibodies against peptide fragments, suggesting pre-vaccination reactivity 456 
to these peptides could be a biomarker for rapidly identifying vaccine responders. (Furman et al., 457 
2013).  458 
Similarly, metabolomic analyses have been notable for describing immune processes by 459 
quantifying the changes in metabolic intermediates perturbed by vaccination or other stimuli 460 
(Diray-Arce et al., 2020). One investigation into the human immune response to shingles virus 461 
vaccination integrated transcriptomic with metabolomics data to elucidate vaccine response 462 
biomarkers. This investigation found early time point metabolites involved in inositol phosphate 463 
metabolism, glycerophospholipid metabolism, and sterol signaling correlated with vaccine-464 
specific T-cell and antibody responses (Li et al., 2017). Furthermore, patients given antibiotics 465 
following human influenza vaccination had decreased influenza virus-specific IgG1, secondary 466 
bile acid metabolites, and increased inflammasome activity compared to vaccinated controls. 467 
These metabolic changes between impaired and unimpaired vaccine responders demonstrated the 468 
combined use of metabolomic, transcriptomic, and microbiomic analyses for identifying a 469 
potential effect of gut dysbiosis on vaccine responsiveness (Hagan et al., 2019). 470 
While proteomic and metabolomic approaches have proven valuable in providing insights 471 
into the dynamic state of vaccine responsiveness, these approaches require expertise and 472 
sophisticated equipment, such as mass spectrometers, that are not available in many labs (Clish, 473 
2015). In addition, depending on the number of samples and analytes, metabolomic profiling can 474 
be highly expensive and time-consuming, potentially restricting their usage to well-funded 475 
laboratories or clinics (Diray-Arce et al., 2020). Therefore, there is need for techniques that can 476 




biology approaches, yet remain cost-effective and do not require a high degree of technical and 478 
analytical specialization.  479 
1.5 Kinomics 480 
Post-translational modifications are covalent changes (i.e. additions, cleavages) to proteins 481 
that modulate aspects of their function, such as changes to activity, cellular localization, or 482 
interaction affinity. Phosphorylation is one of the most fundamental post-translational 483 
modifications for regulating protein function (Rauch et al., 2011). Protein phosphorylation is 484 
mediated by protein kinases that catalyze the transfer of a phosphate group from ATP to the 485 
hydroxyl group of serine, threonine, or tyrosine residues of cellular proteins (Ardito et al., 2017). 486 
Extracellular signals (e.g. pathogen-associated molecular patterns, cytokines) activate kinase-487 
mediated phosphorylation events that initiate intracellular phosphorylation-mediated signaling 488 
cascades and trigger cellular responses, such as gene transcription, cell division, cell motility, and 489 
differentiation (Mogensen, 2009; Rauch et al., 2011; Schroder et al., 2004). The kinetics of protein 490 
phosphorylation permit a rapid cellular response following stimulation. Given that 491 
phosphorylation is an essential mechanism for modulating protein function, there has been a focus 492 
on analyzing the global cellular kinase activity within the cell, or “kinome analysis”, to build upon 493 
the understanding of cellular phenotypes. 494 
One high-throughput approach for analyzing the kinome uses peptide microarrays to 495 
characterize the active kinases catalyzing phosphorylation reactions of kinase-substrates. Proteins 496 
are one such kinase substrate. The kinase’s specific phosphorylation site can be mimicked using 497 
short (15-amino acid) peptides containing the consensus target sequence (Kreegipuu et al., 1998). 498 
These peptides can be printed onto a solid-state array (termed “peptide arrays”) (Jalal et al., 2009). 499 
Biological samples containing active kinases phosphorylate the known peptide substrates on the 500 
peptide array, and the reactions can be quantified using either radiolabeled ATP, phosphorylation-501 
specific antibodies, or staining for phosphorylated residues with fluorescent dyes (Arsenault et al., 502 
2011). Peptide arrays containing a large number of unique peptide substrates have established a 503 
need for software to computationally quantify, transform, and visualize the kinome data (Li et al., 504 
2012; Trost et al., 2013a). Early experiments identifying phosphorylation events following 505 
lipopolysaccharide stimulation of human PBMCs provided proof-of-concept for the use of kinome 506 




integrated for species-specific use, including applications in plants (e.g. barley, Arabidopsis), 508 
insects (e.g. honeybees), and livestock (e.g. cattle, swine, poultry) (Arsenault et al., 2012; Napper 509 
et al., 2015; Régnier et al., 2017; Ritsema et al., 2009; Robertson et al., 2014). Together, the 510 
development and employment of kinome analysis has facilitated the identification of immune-511 
related signaling events for understanding immune mechanisms and discovering drug targets or 512 
biomarkers (Facciuolo et al., 2020). 513 
1.5.1 Identifying Immune Mechanisms using Kinome Analysis 514 
One application of kinome analysis has been to decipher complex, polygenic immune 515 
mechanisms related to pathogenesis and host responses within livestock. For example, bovine 516 
monocytes were infected with Mycobacterium avium subsp. paraturberculosis and kinome 517 
analysis was conducted on lysates of infected and uninfected monocytes to better understand 518 
bacterial pathogenesis. M. avium subsp. paraturberculosis-infected monocytes revealed 519 
differential phosphorylation of proteins involved in interferon-gamma signaling (Arsenault et al., 520 
2012) and TLR9 mediated signaling (Arsenault et al., 2013) compared to uninfected monocytes, 521 
providing insight into the specific molecular mechanisms mediating this host-pathogen interaction. 522 
In a separate investigation, kinome analysis of Ebola virus-infected human liver cells revealed 523 
modulation of TGF-β signaling within host cells. This study led to the identification and 524 
application of kinase inhibitors that increased the survival of Ebola virus-infected mice compared 525 
to untreated, infected controls (Kindrachuk et al., 2014). Other in vitro and ex vivo kinome analyses 526 
have explored the pathogenesis of Mycoplasma bovis and bovine viral diarrhea virus infections in 527 
cattle and Salmonella Enteritidis and Salmonella Heidelberg infections in chicken (He et al., 2018; 528 
Mulongo et al., 2014; Van Wyk et al., 2016). Together, the details of various immune mechanisms 529 
have been elucidated through the analysis of kinase signaling. 530 
1.5.2 Identifying Biomarkers using Kinome Analysis 531 
Kinome analysis has also been pertinent in discovering biomarkers and predicting 532 
phenotypes in the context of stress and disease resilience. An investigation of the responses within 533 
PBMCs of cattle to restraint stress revealed signaling events implicating carbohydrate metabolism 534 
and apoptosis (Chen et al., 2016). This work supported the use of plasma glucose as a simple 535 
biomarker of stress in cattle. In another investigation, Robertson et al. (2014) used kinome analysis 536 




to Varroa mite infestation. These phosphorylation events were subsequently used to predict the 538 
Varroa mite susceptibility of independent honeybee colonies prior to infestation, presenting proof-539 
of-concept that kinome analysis has value in predicting immunity-associated phenotypes 540 
(Robertson et al., 2014, 2020).  541 
1.5.3 Kinases Implicated in the Vaccine Response  542 
Previous transcriptomic investigations on vaccine responses have identified protein kinases 543 
as being differentially expressed when comparing vaccine responders and non-responders. For 544 
example, calmodulin-dependent kinase IV, a kinase involved in dendritic cell survival, was 545 
negatively correlated with humoral responses specific to influenza vaccination in humans (Nakaya 546 
et al., 2011). Similarly, following Yellow Fever-17D vaccination, the kinase eukaryotic initiation 547 
factor 2α-kinase 4 was included in gene expression signatures to predict CD8+ cell responses. 548 
(Querec et al., 2009). Kinases are heavily involved in immune response processes, such as 549 
cytokine and chemokine signaling, cell motility, and leukocyte proliferation and differentiation. 550 
However, aside from scarcely discovering gene expression events of kinases, there has been no 551 
exploration of global kinase activity within blood leukocytes before and after vaccination. Thus, 552 
there is a potential opportunity for kinome analysis to offer new perspectives into vaccine 553 
responses as was provided by other multi-omics studies (Régnier et al., 2017).  554 
1.6. Mycoplasma hyopneumoniae  555 
Mycoplasma hyopneumoniae (M. hyopneumoniae) is an intracellular bacterial pathogen 556 
that is a primary cause of enzootic pneumonia in pigs and also contributes to the porcine respiratory 557 
disease complex (Thacker, 2004). Infection with M. hyopneumoniae is characterized clinically by 558 
a chronic, unproductive dry cough. M. hyopneumoniae is also known to adhere to the ciliated 559 
epithelium of the respiratory tract, leading to a reduction in both cilia and ciliary activity (DeBey 560 
and Ross, 1994). M. hyopneumoniae infection has been found to predispose pigs to concurrent 561 
infections with other pathogens such as swine influenza virus, porcine reproductive and respiratory 562 
syndrome virus, or porcine circovirus type 2 (Thacker, 2004). These viral infections result in  563 
significant economic losses to the pig industry due to decreased performance, reduced growth, 564 
higher treatment costs, and increased mortality of pigs (Maes et al., 2018). Treatment with 565 
antimicrobials has been used to combat M. hyopneumoniae infections, reducing mycoplasmal 566 




of antimicrobial resistance, alternative options such as vaccination are being encouraged 568 
(Laxminarayan et al., 2013). 569 
1.6.1 Mycoplasma hyopneumoniae Vaccines 570 
Vaccination against M. hyopneumoniae has proven effective in decreasing clinical 571 
symptoms (e.g. lung lesions) of M. hyopneumoniae-infection (Maes et al., 2021; Thacker et al., 572 
1998). Many commercial and experimental vaccines for M. hyopneumoniae have used whole-cell 573 
inactivated bacteria (bacterins) or subunit antigens (Djordjevic et al., 1997; Matthijs et al., 2019; 574 
Thacker et al., 1998). For example, RespiSure-One (Zoetis, USA) is an inactivated M. 575 
hyopneumoniae bacterin vaccine containing the adjuvant, Amphigen. RespiSure-One can be given 576 
in one dose as early as 1-day of age to reduce the severity of colonization and shedding of M. 577 
hyopneumoniae. Vaccination using whole-cell bacterins stimulates both humoral and cell-578 
mediated responses (Bandrick et al., 2008). Vaccine-induced serum IgG titers were not correlated 579 
with a reduction in the severity of lung lesions in M. hyopneumoniae-infected piglets, suggesting 580 
that antibody responses are not fully protective against infection and T-cell responses are critical 581 
(Djordjevic et al., 1997).  582 
Piglets vaccinated with different M. hyopneumoniae vaccines have resulted in highly 583 
variable serum antibody responses (Blanc et al., 2021; Matthijs et al., 2019; Munyaka et al., 2020). 584 
As well, M. hyopneumoniae-specific antibodies have been detected in unvaccinated piglets 585 
farrowed from sows which were vaccinated against M. hyopneumoniae vaccines prior to 586 
farrowing, demonstrating piglets can passively acquire vaccine-specific antibody (Sibila et al., 587 
2008). Given that these M. hyopneumoniae vaccines induce variable magnitudes of antibody 588 
responses, they provide a valuable tool for evaluating vaccine immunogenicity. The ability of these 589 
vaccines to stimulate a range of readily quantifiable antibody responses provides an opportunity 590 
to discover biomarkers associated with vaccine responsiveness and interpret the mechanisms the 591 
vaccine-induced immune responses. 592 





Variability in vaccine immunogenicity exists in both humans and livestock. This can result 595 
in vaccine non-responders who remain at risk for infection and threaten individual and population 596 
health. One solution to this problem is to identify biomarkers that can predict vaccine antibody 597 
responders and non-responders. Given the numerous factors that can influence vaccine-induced 598 
immune responses, combined with the necessity of cell signaling to coordinate the vaccine 599 
response, this thesis used kinome analysis to characterize the cell signaling events within 600 
peripheral blood leukocytes collected from pigs prior to vaccination and early after vaccination. 601 
This analysis may provide insight into the immune environment of the host and the resulting 602 
signaling events that follow perturbation, respectively. To establish high vaccine responders and 603 
low vaccine responders, the M. hyopneumoniae vaccine, RespiSure-One, is used to induce variable 604 
vaccine-specific antibody responses. While these antibody responses may not be considered 605 
protective against infection, they were utilized as a metric of vaccine immunogenicity for 606 
identifying early markers of low vaccine responsiveness. 607 
HYPOTHESIS 608 
There are differences in kinase-mediated signaling within porcine PBMCs both before and 609 
after vaccination that are significantly associated with vaccine-induced IgG responses. These 610 
differences in kinase activity can be used to infer molecular mechanisms involved in vaccine 611 
responsiveness and identify biomarkers for predicting an individual’s antibody response to 612 
vaccination. 613 
OBJECTIVES 614 
1. Using a phenotype-first approach, identify high and low vaccine responders to investigate 615 
biochemical and physiological differences that exist prior to and following vaccination as 616 
potential biomarkers for vaccine responsiveness in piglets. 617 
2. Evaluate the predictive capability of physiological and phosphorylation biomarkers within 618 
a second set of high and low vaccine responders. 619 
3. Validate and expand knowledge of the physiological associations identified between 620 
vaccine responsiveness and differences in birth weight and pro-inflammatory cytokines 621 




2. MATERIALS AND METHODS 623 
 624 
2.1 Reagent List 625 
All reagents and chemicals, their suppliers, and their supplier’s addresses are provided (Table 626 
2.1). 627 
Table 1: Reagent, supplier, and supplier address list. 628 
Reagent/Chemical Supplier 
Acetonitrile EMD Biosciences 
Aprotinin Sigma-Aldrich 
Adenosine triphosphate New England Biolabs 
Beta-glycerophosphate Sigma Aldrich 
Bio-Plex Pro magnetic COOH beads Bio-Rad 
Brij-35 Sigma Aldrich 
Bovine serum albumin Sigma-Aldrich 
Ethylene glycol tetraacetic acid (EDTA) Sigma-Aldrich 
Ethylenediaminetetraacetic acid (EGTA) Sigma-Aldrich 
Glycerol GE Healthcare  
Ficoll Sigma-Aldrich 
Fluortrac 200 96F microplate Greiner Bio-One 
Leupeptin Sigma-Aldrich 
Magnesium chloride hexahydrate EMD Biosciences 
Microseal B Adhesive Seals BioRad 
New Zealand pig serum RMBIO 
Phosphate-buffered Saline (PBS) pH 7.4 Sigma-Aldrich 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich 
ProQ Diamond phosphoprotein stain Invitrogen 
RespiSure-One Zoetis Canada Inc. 
Sodium acetate Sigma-Aldrich 
Sodium azide Sigma-Aldrich 
Sodium chloride Sigma-Aldrich 
Sodium fluoride Sigma-Aldrich 
Sodium pyrophosphate Sigma-Aldrich 
Sodium vanadate  Sigma-Aldrich 
Streptavidin R-phycoerythrin  Agilent Technologies 
Triton X-100 Sigma-Aldrich 
Tris Sigma-Aldrich 
Trypan blue Sigma-Aldrich 
Tween 20 Sigma-Aldrich 
Cytokine Supplier 
Interferon alpha (200 pg/mL) Genentech  
Interferon gamma (2000 pg/mL) VIDO-InterVac 




Interleukin 6 (IL-6) 686PI025 (5000 pg/mL) R&D Systems 
Interleukin 8 (IL-8) RP0109S-005 (200 pg/mL) Kingfisher Biotech Inc. 
Interleukin 10 (IL-10) PSC0104 (5000 pg/mL) Fisher Scientific  
Interleukin 12 (IL-12) 912PL025 (5000 pg/mL) R&D Systems 
Interleukin 13 (IL-13) RP0007S-005 (5000 pg/mL) Kingfisher Biotech Inc. 
Interleukin 17 alpha (IL-17α) RP0128S-005 (500 pg/mL) Kingfisher Biotech Inc. 
Tumor Necrosis Factor alpha (TNFα) 690PT025 (5000 
pg/mL) 
R&D Systems 
Capture Antibody Supplier 
Mouse anti-pig IFN-alpha antibody, GTX11408 GeneTex  
Mouse anti-pig IFN gamma antibody, Clone: P2F6, 
ENMP700 
Fisher Scientific 
Mouse anti-Porcine IL-1 beta/IL-1F2 Monoclonal Antibody 
IgG1 Clone # 77724, MAB6811 
R&D Systems 
Goat anti-Porcine IL-6, Polyclonal IgG, AF686 R&D Systems 
Rabbit anti-pig Interleukin-8 Antibody, AHP2392 Bio-Rad Laboratories 
Mouse anti-pig IL-10 Monoclonal Antibody, 
945A4C437B1 
Fisher Scientific 
Mouse anti-swine IL-12 p70 Monoclonal Antibody (clone 
G9), MA0413S 
Kingfisher Biotech Inc. 
Goat anti-swine IL-13 Polyclonal Antibody, PB0094S-100 Kingfisher Biotech Inc. 
Rabbit anti-swine IL-17A Polyclonal Antibody, KP0498S-
100 
Kingfisher Biotech Inc. 
Porcine TNF-alpha Antibody, Monoclonal Mouse IgG1 
Clone # 103304, MAB6902 
R&D Systems 
Detection Antibody Supplier 
Mouse anti-Porcine IFN-alpha Antibody, 27105-1 (200 
ng/mL) 
R&D Systems 
Rabbit anti-Porcine IFN gamma, Polyclonal Antibody, 
PIPP700 (400 ng/mL) 
Fisher Scientific 
Goat anti-Porcine IL-1 beta /IL-1F2 Biotinylated Antibody, 
BAF681 (500 ng/mL) 
R&D Systems 
Goat anti-Porcine IL-6 Biotinylated Antibody, BAF686 
(500 ng/mL) 
R&D Systems 
Goat anti- Porcine IL-8/CXCL8 Biotinylated Antibody, 
BAF535 
(400 ng/mL) 
R&D Systems  
Mouse anti-IL-10 Monoclonal Antibody Biotin, 
945A1A926C2 (500 ng/mL) 
Fisher Scientific 
Mouse anti-Porcine IL‑12/IL‑23 p40 Biotinylated Antibody, 
BAM9122 (500 ng/mL) 
R&D Systems 
Goat anti-Swine IL-13 Polyclonal Antibody – Biotinylated, 
PBB0096S-050 (500 ng/mL) 
Kingfisher Biotech Inc. 
Rabbit anti-Swine IL-17A Polyclonal Antibody – 
Biotinylated, KPB0499S-050 (500 ng/mL) 




Mouse anti-Porcine TNF-alpha Biotinylated Antibody, 
BAM6903 (500 ng/mL) 
R&D Systems 
Supplier Supplier Address 
Agilent Technologies Mississauga, ON, CAN 
Bio-Rad Laboratories Mississauga, ON, CAN 
EMD Biosciences Oakville, ON, CAN 
Fisher Scientific Ottawa, ON, CAN 
GE Healthcare Mississauga, ON, CAN 
Genentech Mississauga, ON, CAN 
GeneTex Irvine, CA, USA 
Invitrogen Oakville, ON, CAN 
Kingfisher Biotech Inc. Burlington, ON, CAN 
New England Biolabs Whitby, ON, CAN 
R&D Systems Toronto, ON, CAN 
Rocky Mountain Biologicals, Inc. (RMBIO) Missoula, MT, USA 
Sigma-Aldrich Oakville, ON, CAN 
VIDO-InterVac Saskatoon, SK, CAN 
VWR Mississauga, ON, CAN 
Zoetis Canada Inc. Kirkland, Quebec, CAN 
 629 
2.2 Animal Housing and Animal Care 630 
This work was approved by the University of Saskatchewan Animal Care Committee (AUP: 631 
AUP20190084) and the University of Alberta Animal Care and Use Committee (AUP: 632 
AUP00001125) following Canadian Council of Animal Care guidelines. All piglets were under 633 
the attention and care of licensed veterinarians. Piglets were monitored for changes in weight gain, 634 
behaviour, and physical injury throughout each trial.  635 
Piglets were weaned at 21 ± 2 days of age and remained grouped with littermates. Piglets were 636 
vaccinated intramuscularly with one dose (1 mL) of RespiSure-One at 28 ± 2 days of age (Day 0) 637 
and received a booster vaccination (1 mL) at 52 ± 2 days of age (Day 24). The trial was terminated 638 
when piglets were 63 ± 2 days of age (Day 35).  639 
In both vaccine trials, M. hyopneumoniae-specific antibodies were not measured for sows. 640 
However, the facilities housing the sows and piglets had not used M. hyopneumoniae vaccines or 641 
infected animals with live M. hyopneumoniae for at least 5 years prior to this study to ensure 642 




The methods from the First Trial (2015) have been previously described in detail (Lipsit et al., 644 
2020) and any modifications made to these methods have been described below. 645 
2.2.1 First Trial (2015) 646 
All sows and piglets were housed and managed at the Swine Research & Technology Centre 647 
(Edmonton, Alberta). Twenty sows (parity = 3-8) bore litters from which 6 piglets (3 males and 3 648 
females) of average-litter birth weight were selected. Piglets that were not of average-litter birth 649 
weight were not monitored for this study. The selected piglets provided a population of 117 healthy 650 
M. hyopneumoniae-free piglets ((Large White × Landrace) × Duroc; 59 male, 58 female). Three 651 
piglets died before the end of the study and were excluded from analyses. Whole blood for PBMC 652 
isolation was collected at 28-(Day 0), 30- (Day 2) and 34- (Day 6) days of age. Plasma was 653 
collected at 28-days (Day 0) of age prior to vaccination, and serum was collected at 63-days of age 654 
(Day 35). Body weight was measured at birth, 24-days of age (weaning), and 63-days of age (Day 655 
35). A nasal swab taken from each piglet on Day 0 confirmed that all animals tested negative for 656 
M. hyopneumoniae.  657 
2.2.2 Second Trial (2020) 658 
All sows and piglets were housed and managed at Prairie Swine Centre (Saskatoon, 659 
Saskatchewan). Six Camborough Plus sows (parity = 0-3) bore litters (n=8-14 piglets/litter) for a 660 
total of 67 piglets (37 male; 30 female). Eleven piglets died prior to the end of this study and were 661 
excluded from analyses. Plasma was collected from piglets at 0-, 7-, 14-, 21-, 28- (Day 0), and 63-662 
days (Day 35) of age. Serum was collected on Day 0 (prior to primary vaccination) and Day 35 663 
(11 days after booster vaccination). Plasma collections consistently took place within the same 664 
two-hour period of the day each week to minimize possible effects of circadian rhythms on plasma 665 
cytokine concentration. Body weight was measured at 0- (birth), 7-, 14-, 21-, 24- (weaning), and 666 
63-days of age. 667 
2.3 Peripheral Blood Mononuclear Cell, Serum, and Plasma Isolation 668 
2.3.1 Peripheral Blood Mononuclear Cell Isolation 669 
Whole blood was collected from the jugular vein using 0.4% EDTA in Ca2+ and Mg2+-free 670 
phosphate-buffered saline (PBS) as an anticoagulant. Whole blood was centrifuged at 1400 x g for 671 
20 min without brake, and the buffy coat was collected and diluted 1:2 in PBS + 0.1% EDTA. 672 




PBMCs were collected from the interphase of the Ficoll and the plasma, washed with cold PBS + 674 
0.1% EDTA and centrifuged at 300 x g at 4 °C for 8 min. PBMC pellets were washed with cold 675 
PBS and centrifuged at 300 x g, 4 °C for 8 min twice. PBMCs were counted using trypan blue 676 
exclusion using a hemocytometer. PBMC pellets of 10 x 106 cells were flash-frozen in liquid 677 
nitrogen and stored at -80 °C for kinome analysis. 678 
2.3.2 Serum and Plasma Isolation 679 
Whole blood from the jugular vein was collected into serum separation tubes and K2EDTA-coated 680 
Vacutainer tubes (Becton Dickinson) to isolate serum and plasma, respectively. Serum tubes were 681 
incubated at room temperature for 30 min. Serum and plasma tubes from the 2015 trial were 682 
centrifuged at 15,000 x g for 10 mins, 4 °C. Serum and plasma tubes from the 2020 trial were 683 
centrifuged at 2000 x g for 20 mins, 4 °C without break. Aliquots of serum and plasma were stored 684 
at −80 °C. 685 
2.4 Serum Mycoplasma hyopneumoniae-IgG Quantification 686 
2.4.1 First Trial (2015) 687 
One mL serum from each piglet collected on Day 35 was shipped to Biovet (Saint—Hyacinthe, 688 
Quebec, Canada), where serum M. hyopneumoniae-specific IgG titers were quantified using an 689 
IDEXX Mycoplasma hyopneumoniae Antibody Test Kit ELISA (IDEXX Laboratories, Inc.). M. 690 
hyopneumoniae-specific IgG titers were transformed using a z-score Log2 scale.  691 
Plasma collected on Day 0 from high (n=10) and low (n=10) responders was centrifuged (20,000 692 
x g, 30 min) and shipped to Prairie Diagnostic Services (Saskatoon, SK, Canada), and M. 693 
hyopneumoniae-specific antibody titers were quantified using an IDEXX Mycoplasma 694 
hyopneumoniae Antibody Test Kit ELISA (IDEXX Laboratories, Inc.). Samples were considered 695 
seronegative for M. hyopneumoniae-specific IgG if the S/P ratio (
𝑆𝑎𝑚𝑝𝑙𝑒𝐴650 −𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐴650
𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝐴650−𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝐴650
) at a 696 
1:40 dilution was S/P<0.3 and seropositive if S/P>0.4, as per the manufacturer’s instructions. 697 
Positive and negative controls were commercially (IDEXX Laboratories, Inc.) provided porcine 698 
anti-M. hyopneumoniae serum and porcine serum non-reactive to M. hyopneumoniae, respectively. 699 
2.4.2 Second Trial (2020) 700 
One mL serum collected on Day 0 and Day 35 from each piglet was shipped to Prairie Diagnostic 701 




using an IDEXX Mycoplasma hyopneumoniae Antibody Test Kit ELISA (IDEXX Laboratories, 703 
Inc.). Serum was considered seronegative for M. hyopneumoniae-specific IgG if the S/P ratio at a 704 
1:40 dilution was S/P<0.3 and seropositive if S/P>0.4, as per the manufacturer’s instructions. 705 
Serum M. hyopneumoniae-specific IgG titers were determined for each piglet on Day 35 and 706 
quantified using a modified endpoint titration ELISA (IDEXX M. hyo Ab Test Kit ELISA). 707 
Briefly, Day 35 sera were serially diluted 1 in 4 starting with an initial 1:40 dilution. ELISA 708 
reactions were quantified using A650 absorbance. Endpoint titers were calculated by subtracting 709 
the negative control A650 and taking the reciprocal of the highest dilution with an A650 absorbance 710 
greater than the mean negative control. Endpoint titration ELISAs were completed by Biovet 711 
(Saint-Hyacinthe, QC, Canada). 712 
2.5 Stratification of High and Low Responders 713 
2.5.1 First Trial (2015) 714 
Twelve piglets were stratified into a discovery cohort of low (LR; n=6) and high (HR; n=6) 715 
responders using the 10th percentile and 90th percentile of serum IgG titers, respectively. Eight 716 
additional piglets were selected from the 20th percentile and 80th percentile of serum IgG titers for 717 
a validation cohort of low (n=4) and high (n=4) responders, respectively. Multiple animals were 718 
excluded from LR and HR cohorts based on the availability of archived samples. These piglets 719 
were, however, included in the M. hyopneumoniae-specific IgG titer population analysis. HR5 (ID: 720 
“338B”) had usable Day 0 and Day 2 samples but not on Day 6. Therefore, HR5 was included in 721 
the validation cohort for Day 0 and Day 2 analyses but was substituted with another HR (ID: 722 
“893R”, HR11) for Day 6 analyses.  723 
2.5.2 Second Trial (2020) 724 
Twelve piglets within the 10th and 90th percentile of serum IgG titers, respectively, were stratified 725 
as LR (n=6) and HR (n=6) to match the discovery cohort of the first trial (2015).  726 
2.6 Kinome Array Experiment 727 
Frozen pellets of 10 x 106 PBMCs were lysed with ice-cold lysis buffer (20 mM Tris-HCl (pH 728 
7.5), 150 mM sodium chloride, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium 729 
pyrophosphate, 1 mM sodium vanadate, 1 mM sodium fluoride, 1 μg/mL leupeptin, 1 μg/mL 730 
aprotinin, 1 mM PMSF) and incubated for 10 min on ice. Lysates were centrifuged for 10 min at 731 




60 mM MgCl2, 0.05% Brij-35, and 0.25 mg/mL bovine serum albumin) for 10 min on ice. Samples 733 
were incubated on the peptide array for 2 h at 37 °C. Arrays were washed with PBS + 1% Triton 734 
X-100, submerged in ProQ Diamond phosphoprotein stain, and incubated for 1 h with agitation. 735 
Arrays were destained with 20% acetonitrile + 50 mM sodium acetate, pH 4.0 for 10 min. Arrays 736 
were washed with distilled deionized water and centrifuged for 5 min at 800 x g to remove excess 737 
moisture. Phosphorylation intensity was collected using a GenePix Professional 4200A 738 
Microarray Scanner at 532 nm to 560 nm with a 580 nm filter. Images were captured using the 739 
GenePix Pro 6.0 software (MDS) to collect spot intensity. Kinome array experiments for each time 740 
point (Day 0, Day 2, and Day 6) were conducted independently. 741 
2.7 Kinome Array Data Transformation and Analysis 742 
2.7.1 Data Transformation 743 
Peptide microarrays (JPT Peptide Technologies, Berlin, Germany) with 282 unique peptides 744 
representing sequences surrounding selected phosphorylation sites within specific porcine proteins 745 
were utilized for this study (Jalal et al., 2009; Li et al., 2012). Each peptide was 15 amino acids in 746 
length and represented by 9 technical replicate spots on the peptide microarray. Individual 747 
phosphorylation intensities were determined by subtracting the background F632 intensity from 748 
the foreground F632 intensity using Platform for Integrated, Intelligent Kinome Analysis 749 
(PIIKA2) software (Trost et al., 2013a). PIIKA2 subtracted background intensities from 750 
foreground intensities and transformed differences using variance-stabilizing normalization 751 
(VSN). Arrays from the discovery cohort at all time points were transformed together, independent 752 
of the validation cohort. Arrays from the validation cohort at all time points were subsequently 753 
transformed with the discovery cohort datasets to allow for comparable scales. The technical 754 
replicates were averaged together and fold-change (FC) for each peptide phosphorylation 755 
intensities was calculated using Log2 values. FC=2^d, where “d = (average intensity of group y – 756 
average intensity of group x)”. The negative reciprocal of FC was calculated when d<1 for 757 
interpretation purposes.  758 
2.7.2 Principal Component Analysis 759 
Principal component analysis (PCA) was conducted and visualized using ClustVis version 1.0 with 760 
the parameters: transformation = “no transformation”, Row scaling = “unit variance scaling”, PCA 761 




2.7.3 Pathway Analysis 763 
Functional enrichment analysis of differential phosphorylation events was performed using 764 
gProfiler on default parameters (Raudvere et al., 2019). Results were considered statistically 765 
significant at a threshold of p≤0.05. 766 
2.8 Fluorescent Microsphere Immunoassay 767 
All incubations were done at room temperature with agitation at 750 rpm. Plates were covered in 768 
foil to reduce light exposure. Following each incubation, plates were washed with PBS pH 7.4 + 769 
0.5% Tween 20 using a Bio-Plex PRO II wash station (30-sec soak, 3 cycles). Antibodies for IFNα, 770 
IFNγ, IL-1β, IL-6, IL-8, IL-12, IL-13, IL-17α and TNFα were conjugated to individual BioPlex 771 
Max-Plex C magnetic beads (BioRad) using a method previously described (Christopher-772 
Hennings et al., 2013). TNFα multiplex analysis was conducted on a separate plate to avoid cross-773 
reactivity (Table 2.2). 774 
Cytokine standards were diluted 1:3 in New Zealand pig serum to account for serum inhibitory 775 
effects. Plasma samples from Trial 2015 were diluted 1:2 and 1:4 in porcine diluent (PBS, 1% 776 
New Zealand pig serum, 0.05% sodium-azide). Plasma samples from Trial 2020 were diluted 1:3 777 
in the porcine diluent. All plasma samples were run in triplicate. Plasma samples were incubated 778 
for 1 h with 1200 beads/well in a Fluortrac 200 96F microplate. After a wash, samples were 779 
incubated for 30 min with specific biotinylated antibodies specific to the corresponding cytokine. 780 
After another wash, samples were incubated for 30 min with 5 μg/mL streptavidin R-phycoerythrin 781 
conjugate. After a final wash, samples were incubated for 5 min with TE buffer (50 mM Tris, 782 
25mM EDTA, pH 8.0). Plates were read on a BioPlex 200 reader (Bio-Rad Laboratories Inc.) with 783 
the settings “50 beads per region, 45-second time-out, and 60 μL volume”. All replicates and 784 
dilution factors for each animal were averaged for a final sample concentration. Technical 785 
replicates below the lower limit of quantification were not calculated in the average result. Samples 786 
below the limit of detection were recorded as ½ the lower limit of quantification value. Lower 787 
limit of quantification values for all cytokines were: IFNα (1.57 pg/mL), IFNγ (14.4 pg/mL), IL-788 
1β (37.5 pg/mL), IL-6 (40.3 pg/mL), IL-8 (2.72 pg/mL), IL-12 (39.1 pg/mL), IL-13 (40.0 pg/mL), 789 
IL-17α (15.5 pg/mL), and TNFα (39.8 pg/mL). 790 
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2.9 Statistical and Data Analysis 795 
All data analysis and visualization were performed using GraphPad Prism version 9.0 796 
(GraphPad Software, San Diego, California USA). The correlation matrix (Fig. 12A) was created 797 
in R using the package corrplot (Wei and Simko, 2021). P-values were considered statistically 798 
significant at p≤0.05, and were considered to be a statistical trend at 0.05<p≤0.1. 799 
2.9.1 First Trial (2015) 800 
The Log2-transformed serum M. hyopneumoniae-specific IgG titer data and the variance-801 
stabilizing normalization-transformed kinome data were determined to be normally distributed 802 




distribution as the sample size (n=117) was large, the samples were measured independently, and 804 
the mean (1.48 kg) was approximately the median (1.5 kg). Plasma cytokine concentrations from 805 
the discovery cohort and validation cohort were determined to not be normally distributed (one-806 
sample Kolmogorov-Smirnov test, p<0.1). A two-tailed unpaired Student’s t-test was conducted 807 
to analyze differences in Log2-transformed serum M. hyopneumoniae-specific IgG titer, and 808 
weight at birth, weaning, or the end of the trial, between HR and LR within the discovery cohort. 809 
A Mann-Whitney U-test was conducted to determine differences in cytokine concentrations 810 
between HR and LR in the discovery cohort. A Mann-Whitney U-test was conducted to analyze 811 
differences in Log2-transformed serum M. hyopneumoniae-specific IgG titer, plasma cytokine 812 
concentrations, birth weight, and weaning weight between HR and LR within the validation cohort. 813 
A Pearson linear regression was conducted for the correlation analysis of Log2-transformed serum 814 
M. hyopneumoniae-specific IgG titer and birth weight. A Spearman Rank Correlation was 815 
conducted to correlate Log2-transformed serum M. hyopneumoniae-specific IgG titer and plasma 816 
IFNγ concentrations.  817 
A repeated-measures two-way ANOVA with Geisser-Greenhouse correction was 818 
conducted using the average transformed intensity for each peptide with the factors “Day” and 819 
“Response” to determine differential phosphorylation events between HR and LR within the 820 
discovery cohort. Sidak’s multiple comparisons were conducted between HR and LR within the 821 
discovery cohort for each Day. A false-discovery rate (FDR) of 5% was applied using a Benjamini-822 
Hochberg Correction to P-values for each Day. Phosphorylation events were considered 823 
differentially phosphorylated under two criteria: there was an effect (p<0.05) of either the 824 
“Response” variable or the “Response x Day” variable, and there was a difference (FDR<0.05) 825 
between HR and LR after FDR-correction. A Mann-Whitney U-test was conducted to analyze 826 
differences in mean phosphorylation intensity between HR and LR in the validation cohort.  827 
2.9.3 Second Trial (2020) 828 
The Log2-transformed M. hyopneumoniae-specific serum IgG titer from the second trial 829 
was treated as normally distributed as the sample size (n=67) was large, samples were measured 830 
independently, and the mean (11.6) approximated the median (11.8). A two-sided Kolmogorov-831 
Smirnov test was used to test if the distributions of Log2-transformed M. hyopneumoniae-specific 832 




with Welch’s correction was used to determine differences in titers of HR between trials and 834 
differences in titers of LR between trials (F-test of equality of variances, p<0.05). Plasma cytokine 835 
concentrations were not normally distributed on individual days (Kolmogorov–Smirnov test, 836 
p<0.1). Therefore, a Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparisons was 837 
used to detect differences in IFNγ and IL-1β concentrations when comparing among days. Plasma 838 
cytokine concentrations were normally distributed when grouped by litter (Kolmogorov–Smirnov 839 
test, p>0.1). Therefore, a two-way ANOVA with a Geisser-Greenhouse correction was conducted 840 
using the factors “Litter” and “Day”. Tukey’s multiple comparisons were conducted between 841 
litters on each Day due to the effect of “Litter x Day” (p<0.001). A one-way ANOVA was 842 
conducted to detect a mean difference in Log2-transformed M. hyopneumoniae-specific IgG titers 843 
between litters. A Spearman Rank Correlation was conducted to correlate Log2-transformed M. 844 
hyopneumoniae-specific IgG titer and plasma cytokine concentrations. The body weight of all 845 
piglets at birth, weaning, and at the end of the trial were determined to be normally distributed 846 
(Kolmogorov–Smirnov test, p>0.1). A two-tailed, unpaired Student’s t-test with Welch’s 847 
correction was conducted to analyze mean differences in birth, weaning, and end of trial weight 848 
between HR and LR and mean differences in Log2-transformed M. hyopneumoniae-specific IgG 849 
titer between the highest and lowest birth weight piglets. 850 




3. RESULTS 852 
 853 
3.1 Identifying Vaccine Response Biomarkers in a Discovery Cohort 854 
Results from Section 3.1 have been previously described (Lipsit et al., 2020). Modifications to 855 
statistical tests, sample cohorts, and visualizations have been made and are described here. 856 
3.1.1 Variation of M. hyopneumoniae-specific IgG Titers following Vaccination 857 
A population of piglets (n=117; 58 male, 59 female) selected from 20 litters (6 piglets/litter; 858 
3 male, 3 female) were vaccinated with a commercial M. hyopneumoniae vaccine (RespiSure-One; 859 
Zotetis) at 28- and 52-days of age (Day 24). Serum M. hyopneumoniae-specific IgG titers were 860 
quantified at 63-days of age (Day 35) using an IDEXX M. hyo Ab ELISA. Piglets exhibited a 861 
broad variation in serum M. hyopneumoniae-specific IgG titers 11-days following the booster 862 
vaccination (range, 5.85-13.67; median, 9.96) (Fig. 1A). No sex-dependent effect was observed 863 
when comparing serum IgG titers (p=0.34; Student’s T-test with Welch’s correction). Samples 864 
were collected from piglets in 4 batches and no batch-dependent effect was observed (p>0.99; 865 
ordinary one-way ANOVA). There was a mean difference in serum IgG titers among the 20 litters 866 
selected for this study (p=0.047; ordinary one-way ANOVA). However, multiple comparisons 867 
among all litters failed to identify significant differences between any two litters (p>0.11; Tukey’s 868 
multiple comparisons) and all litters were included in subsequent analyses. To classify piglets as 869 
seronegative (S/P<0.3), suspected (0.3<S/P<0.4), and seropositive (S/P>0.4), thresholds of serum 870 
IgG titers were calculated at Log2 values of 9.27 (S/P=0.3) and 9.72 (S/P=0.4) based on 871 
instructions from the ELISA manufacturer (IDEXX). Thus, this trial population consisted of 36 872 
seronegative, 65 seropositive, and 16 suspected animals for M. hyopneumoniae on Day 63. 873 
Within this trial, high (HR) responders (n=6; titer range = 12.13-13.67; median = 12.81) 874 
and low (LR) responders (n=6; titer range = 5.85-7.65; median = 7.19) were stratified based on 875 
serum IgG titers at Day 35 to establish a “discovery cohort” (Fig. 1B). HR from this discovery 876 
cohort had a 48-fold greater (p<0.001) median serum M. hyopneumoniae-specific IgG titers than 877 
LR. While other piglets (empty shapes) shown in (Fig. 1A) may have had higher titers than HR 878 
and lower titers than LR subjects, they were excluded from HR and LR cohorts due to a lack of 879 
PBMCs required for kinome analysis. HR and LR were seronegative (S/P<0.1) for M. 880 
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Figure 1: Defining high and low responders among vaccinated piglets (Trial 2015) using 883 
Mycoplasma hyopneumoniae-specific IgG titers 11-days following booster RespiSure-One 884 
vaccination. A. Variability of M. hyopneumoniae-specific IgG titers among piglets in Trial 2015 885 
(n=117; open and solid symbols). Solid symbols indicate high (HR; n=6; circles) and low (LR; 886 
n=6; squares) responders selected for further study. B. Comparison of median M. hyopneumoniae-887 
specific IgG titers of HR and LR selected for the discovery cohort. Dashed and dotted lines 888 
represent the threshold for seropositive and seronegative cutoffs, respectively. P-values were 889 
determined using a two-tailed, unpaired Student’s t-test. Figures 1A and 1B are modified from 890 
Lipsit et al. (2020). 891 




3.1.2 Kinome Analysis of Pre-vaccination PBMCs 893 
Kinome analysis was performed on PBMCs collected immediately prior to vaccination 894 
(Day 0) and 2- and 6- days post-vaccination (Days 2 and 6) from HR and LR within the discovery 895 
cohort that were to determine the phosphorylation events within blood leukocytes associated with 896 
vaccine responses. PBMC lysates were incubated over peptide microarrays containing 282 unique 897 
peptide targets representing known phosphorylation sites of porcine proteins. The magnitude of 898 
phosphorylation of each peptide target was quantified to generate a kinome profile for each piglet.  899 
3.1.2.1 Principal Component Analysis of Global Kinome Profiles 900 
Principal component analysis (PCA) was conducted on HR and LR for each Day using the 901 
282-phosphorylation event kinome profile. PCA is a method of unbiased cluster analysis that 902 
separates samples with a large number of variables into fewer dimensions (called “principal 903 
components”) that retain the variability of the original data (Jolliffe and Cadima, 2016). There was 904 
a high intra-group similarity within LR subjects on Day 0, suggesting similar kinome activities 905 
prior to vaccination. In contrast, HR displayed greater variability when considering the 906 
phosphorylation events of all 282 peptide targets (Fig. 2A). Kinome profiles on Day 2 did not 907 
cluster separately based on vaccine responsiveness phenotypes and showed overlapping 95% 908 
confidence intervals between LR and HR kinome profiles (Fig. 2B). Finally, PCA of Day 6 kinome 909 
profiles revealed that PC1 (23.3%) could separate HR and LR kinome profiles when considering 910 
the 282-kinome profile, suggesting multiple phosphorylation events were different between HR 911 
and LR (Fig. 2C). Comparative analysis of individual HR and LR phosphorylation events was 912 
conducted to reveal specific phosphorylation biomarkers that strongly associated with vaccine 913 
responsiveness.  914 








Figure 2: Principal component analysis of the high and low responders from the discovery 917 
cohort. Principal component analysis of high (HR; n=6; green) and low (LR; n=6, orange) 918 
responders using phosphorylation events of 282 peptides on A. Day 0, B. Day 2, and C. Day 6. 919 
The two principal components (PC) with the highest variance (%) are shown. Ellipses represent 920 
95% confidence intervals for each phenotypic group. 921 




3.1.2.2 Comparative analysis of high and low responders  923 
A repeated-measures two-way ANOVA using the factors “Response” (High vs Low) and 924 
“Time” (Day 0 vs Day 2 vs Day 6) was conducted using a post-hoc Sidak’s multiple comparisons 925 
test to identify significantly different phosphorylation events between HR and LR. A false-926 
discovery rate (FDR) of 0.05 (5%) was applied to the 282 tests on each time point using the 927 
Benjamini-Hochberg method. FDR corrections are helpful in big data analyses to reduce the 928 
number of false-positive results from conducting multiple hypothesis testing.  929 
3.1.2.3 Differences prior to vaccination (Day 0) 930 
On Day 0, 10 differential (FDR-corrected P-value<0.05) phosphorylation events were 931 
identified between HR and LR on Day 0 (Table 3). Eight of the 10 phosphorylation events had 932 
higher levels of phosphorylation (FC>1) in LR compared to HR. Within the Day 0 list, there was 933 
differential phosphorylation of peptide targets representing mediators of immune-function such as 934 
B-cell linker protein (BLNK), IL-6 receptor (IL6ST), TNF receptor-associated factor 6 (TRAF6), 935 
and cell signaling mediators such as AKT1, protein phosphatase 2 catalytic subunit alpha 936 
(PPP2CA), and calmodulin (CALM1).  937 
3.1.2.4 Differences following vaccination (Day 2 and 6) 938 
No individual phosphorylation events were significantly different between HR and LR at 939 
an FDR of 5% on Day 2 (Table 3). However, on Day 6, 11 differential (FDR-corrected P-940 
value<0.05) phosphorylation events were identified between HR and LR (Table 3). Within the 941 
Day 6 list, differential phosphorylation events were observed on peptide targets representing 942 
proteins involved in mediating cell signaling, such as phosphoinositide-3-kinase regulatory 943 
subunit 1 (PIK3R1) and receptor of activated C kinase 1 (RACK1), cytoskeletal proteins like 944 
stathmin 1 (STMN1) and PPP2CA, and proteins with known immunological signaling functions 945 
like TRAF6, SYK, and nuclear factor of activated T-cells, cytoplasmic 1 (NFATC1). Seven of the 946 
11 differential phosphorylation events had higher levels of phosphorylation (FC>1) in the LR than 947 
the HR. 948 
In comparing the biomarkers determined on Day 0 and 6, three identical phosphorylation events 949 
(TRAF6_Y353, STMN1_S15, and PPP2CA_T304) were consistent over time with similar fold-950 
changes at each time point. Together, these results demonstrate that molecular differences between 951 




Table 3: Differential phosphorylation events within PBMCs between low and high 953 
responders on Day 0 and Day 6 in the discovery cohort. 954 
 Target Name Target Site UniProt ID FDRa q-value FCb 
Day 0 
TRAF6 Y353 Q9Y4K3 0.014 -2.33 
AKT1 T308 P31749 0.021 -2.10 
PPP2CA T304 P67775 0.016 -2.04 
STMN1 S15 P16949 0.014 -1.89 
STAT4 S722 Q14765 0.025 -1.88 
FGFR1 Y653 P11362 0.016 -1.70 
CALM1 Y99 P0DP23 0.016 -1.66 
RPS6KB1 S447 P23443 0.040 -1.62 
BLNK Y178 Q8WV28 0.016 1.55 
IL6ST S782 P40189 0.016 1.75 
 
Day 6 
STMN1 S37 P16949 0.014 -2.66 
TRAF6 Y353 Q9Y4K3 0.014 -2.16 
PPP2CA T304 P67775 0.014 -1.96 
RAB5A T202 P20339 0.014 -1.84 
RACK1 Y194 P63244 0.025 -1.80 
PIK3R1 Y556 P27986 0.014 -1.65 
STMN1 S15 P16949 0.014 -1.62 
KEAP1 Y141 Q14145 0.036 1.27 
SMAD1 S214 Q15797 0.014 1.40 
SYK Y348 P43405 0.036 1.48 
NFATC1 S245 O95644 0.014 2.41 
 955 
a False-discovery rate (FDR) was applied to Sidak’s multiple comparison tests between high and 956 
low responders on each time point. FDR was set at 0.05.  957 
b Fold-change (FC) is calculated as a change from low responders (x) to high responders (y). 958 




3.1.3. Pathway analysis with Gprofiler 960 
To determine potential functions associated with differentially phosphorylated peptides 961 
between HR and LR, a functional enrichment analysis using Gprofiler (version 962 
e104_eg51_p15_3922dba), an online software for conducting over-representation analysis, was 963 
performed for each time point. Functional enrichment analysis finds statistically significant cell 964 
signaling pathways and processes involving the genes/proteins within the query set. Thus, it may 965 
provide insight into the function of the differential phosphorylation events. Fold-changes and 966 
target sites of peptides were not included in the analysis because the function of all phosphorylation 967 
sites are not curated in the databases being queried. 968 
3.1.3.1 Pathway analysis of Day 0 969 
Functional enrichment of the protein IDs corresponding to the differential phosphorylation 970 
events contributed to numerous immune-associated signaling pathways, including “Signaling by 971 
Interleukins” (Reactome; p=3.1x10-4), “Cytokine Signaling in the Immune System” (Reactome; 972 
p=3.5x10-3), IL-6 signaling pathway (WikiPathways; p=1.8x10-3), and Interleukin-11 Signaling 973 
Pathway (WikiPathways; p=1.9x10-3). The protein IDs contributing to the enrichment pathways 974 
included TRAF6, BLNK, IL6ST, PPP2CA, AKT1, and STAT4. Overall, there was a high 975 
representation of pathways implicating differential phosphorylation of proteins involved in 976 
cytokine signaling within PBMCs prior to vaccination. 977 
3.1.3.2 Pathway analysis of Day 6 978 
Repeating the functional enrichment analysis with the differential phosphorylation events 979 
on Day 6 revealed pathways such as “Fc epsilon receptor (FCERI) signaling” (Reactome; 980 
p=4.4x10-3), “RANKL/RANK (Receptor activator of NFKB (ligand)) Signaling” (WikPathways; 981 
p=4.5x10-5) and “B cell receptor signaling pathway” (KEGG; p=6.1x10-3). The protein IDs that 982 
contributed to these enrichments included TRAF6, NFATC1, PPP2CA, and PIK3R1. However, 983 
the enrichment analysis of the Day 6 differential phosphorylation events did not elude biological 984 
processes that could be verified with readily available plasma samples. 985 
The Day 0 functional enrichment analysis suggested differential cytokine signaling 986 
between HR and LR prior to vaccination. Multiplex assays have been developed and validated in 987 




2010) Together, this led to the investigation of plasma cytokines concentrations prior to 989 
vaccination within HR and LR. 990 
3.1.4 Multiplex Plasma Cytokine Analysis 991 
The numerous cytokine signaling pathways identified in the functional enrichment analysis 992 
of HR and LR PBMCs prior to vaccination suggested there could be differences in cytokine 993 
signaling. To determine if cytokine signaling pathways were differentially active in HR and LR 994 
prior to vaccination, nine cytokines (IFNα, IFNγ, IL-1β, IL-6, IL-8, IL-12, IL-13, IL-17α, and 995 
TNFα) were quantified in plasma collected on Day 0. LR had a higher (p=0.016) plasma 996 
concentration of IFNγ compared to HR (Fig. 3A). Furthermore, within the HR and LR, there was 997 
a significant (p=0.028) negative (r=-0.64) correlation between plasma IFNγ concentrations on Day 998 
0 with vaccine-induced serum IgG titers on Day 35 (Fig. 3B). There was also a trend of higher IL-999 
1β (p=0.06) plasma concentrations within LR compared to HR (Fig. 3A). Additional samples are 1000 
needed to determine if there were a difference in plasma TNFα (p=0.12) between HR and LR (Fig. 1001 
3A). HR and LR showed no significant difference (p>0.05) in IFNα, IL-6, IL-8, IL-12, IL-13, or 1002 
IL-17α plasma concentrations on Day 0 (Fig. 3C). Correlation analyses were not conducted for 1003 
IL-1β and TNFα due to the low number of data points available for these cytokines in the HR and 1004 
LR cohorts. These data suggest that elevated pro-inflammatory cytokines circulating in the blood 1005 
prior to vaccination negatively associate with vaccine responses.  1006 
































































































Figure 3: High and low responders differ in plasma concentration for multiple pro-1009 
inflammatory cytokines prior to vaccination. A. Comparison of median plasma concentrations 1010 
of IFNγ, IL-1β, and TNFα between high (HR; n=6; open circles) and low (LR; n=6; closed circles) 1011 
responders on Day 0 (prior to vaccination). B. Correlation analysis between M. hyopneumoniae-1012 
specific IgG titers and Day 0 IFNγ plasma concentrations within HR and LR. Best fit lines 1013 
determined using Spearman Correlation. C. Comparison of median plasma concentrations of 1014 
IFNα, IL-6, IL-8, IL-12, IL-13, and IL-17α between HR and LR on Day 0. P-values were 1015 
determined using a Mann-Whitney U-test. Figures 3A and 3B are modified from Lipsit et al. 1016 
(2020). 1017 




3.1.5 Body Weight Analysis of Vaccine Responders 1019 
Body weight is a common metric for evaluating livestock health and their likelihood of 1020 
animal survival (Milligan et al., 2002a). Therefore, piglet body weight at birth, weaning (24-days 1021 
of age), and at the end of the trial (63-days of age) were investigated for potential relationships 1022 
with vaccine responsiveness.  1023 
There was considerable variation in birth weights (range, 1.0-1.9 kg; mean, 1.5 kg), 1024 
weaning weights (range, 4.6 – 10 kg; mean, 6.9 kg), and trial end weights (range, 19 – 38 kg; 1025 
mean, 25 kg) among piglets. LR had lower birth weight (p=0.002) and lower weaning (p=0.035) 1026 
weight compared to HR (Fig. 4A). At the end of the experiment (63-days of age), there was no 1027 
difference (p=0.28) in weight between HR and LR, which suggests that LR did not have inherent 1028 
long-term growth impairments compared to the HR (Fig. 4A). Within the HRs and LRs, there was 1029 
a significant (p=0.002) positive (r=0.63) correlation between birth weight and serum IgG titer (Fig. 1030 
4B). However, a strong (p=0.024; r=0.04) correlation between birth weight and serum IgG titer 1031 
was not evident within the entire (n=117) trial population (Fig. 4C). Therefore, associations 1032 
between vaccine responsiveness, plasma IFNγ concentrations, and birth weight observed within 1033 
the highest and lowest vaccine antibody responders are not apparent across the entire population. 1034 







































































































Figure 4: Body weight is associated with vaccine responsiveness in high and low responders 1037 
prior to vaccination. A. Comparison of median body weight between high (HR; n=6; open 1038 
circles) and low (LR; n=6; closed circles) responders at birth, weaning (24-days of age), and at the 1039 
end of the trial (63-days of age). B. Correlation analysis between M. hyopneumoniae-specific IgG 1040 
titers and piglet birth weight of HR and LR. C. Correlation analysis between M. hyopneumoniae-1041 
specific IgG titers and piglet birth weight for the trial population. P-values were determined using 1042 
a two-tailed, unpaired Student’s t-test. Best fit lines determined using Pearson Correlation. Figures 1043 
4A, 4B, and 4C are modified from Lipsit et al. (2020). 1044 




3.1.6 Conclusions to Section 3.1 1046 
Vaccinating a trial population of piglets with a two-dose regimen of RespiSure-One 1047 
resulted in broad variation in vaccine-induced antibody responses. Approximately 31% of piglets 1048 
were considered seronegative for M. hyopneumoniae-specific antibodies at 11-days following 1049 
booster vaccination. High and low vaccine responders were apparent and revealed multiple 1050 
variables associated with vaccine responsiveness. Kinome analysis of PBMCs collected from HR 1051 
and LR highlighted molecular differences among vaccine responders immediately before and 6-1052 
days after vaccination. The pre-vaccination differential phosphorylation events were associated 1053 
with cytokine signaling pathways and elevated plasma IFNγ and IL-1β within LR compared to HR 1054 
were consistent with kinome data. These data align with the observations of others who identified 1055 
higher concentrations of serum cytokines in low vaccine responders at the time of vaccination 1056 
(Fourati et al., 2016; Frasca et al., 2014; Trzonkowski et al., 2003). Also, LR and HR had 1057 
differences in body weight prior to vaccination, specifically at birth and weaning. Similar 1058 
observations between birth weight and vaccine responsiveness were reported for human infants 1059 
and adolescents following typhoid vaccination (McDade et al., 2001; Moore et al., 2004). These 1060 
data support using birth weight and plasma cytokine levels as biomarkers for detecting likely low 1061 
responders in a herd of piglets. Further exploration of whether these variables are host 1062 
characteristics that affect vaccine responsiveness or are indicators of immunological mechanisms 1063 
that affect vaccine responsiveness is required. Since validation that these biomarkers are consistent 1064 
in other vaccine responders was needed, the relationships between vaccine responsiveness, 1065 
phosphorylation events, plasma cytokines, and body weight were investigated in a second cohort 1066 
of high and low vaccine responders. 1067 
3.2 Validating Vaccine Response Biomarkers in a Validation Cohort 1068 
3.2.1 Establishing a Validation Cohort of High and Low Responders 1069 
A second cohort of HR (n=4) and LR (n=4) corresponding to the 80th and 20th percentile 1070 
of serum IgG titers were stratified as a validation cohort to test the predictive capability of the 1071 
biomarkers identified in the discovery cohort. HR and LR within the validation cohort were 1072 
seronegative (S/P<0.1) prior to vaccination. HR within the validation cohort had higher (p=0.038) 1073 
serum IgG titers than the LRs in the validation cohort. When comparing HR between the discovery 1074 
and validation cohorts, validation HR had a lower rank-sum difference (p=0.029) than discovery 1075 




Thus, the validation cohort consists of high and low responders with a more moderate phenotype 1077 
than the discovery cohort. 1078 












































Figure 5: High and low responders from the validation cohort have less divergent serum IgG 1081 
titers 11-days following booster RespiSure-One vaccination than the discovery cohort. 1082 
Median M. hyopneumoniae-specific IgG titers of high (HR; empty shape) and low (LR; filled 1083 
shape) responders within the discovery cohort (squares; n=6/cohort) and the validation cohort 1084 
(circles; n=6/cohort). Dashed and dotted lines represent the threshold for seropositive and 1085 
seronegative cutoffs, respectively. P-values were determined using a Mann-Whitney U-Test. 1086 




3.2.2 Biochemical and Physiological Markers within the Validation Cohort  1088 
In the discovery cohort, LR had higher levels of plasma IFNγ, IL-1β, and TNFα on Day 0 1089 
than HR (Fig. 3A). The discovery cohort also revealed LR had lower body weight at birth and 1090 
weaning than HR (Fig. 4A). Therefore, these plasma cytokines and body weights were quantified 1091 
in HR and LR within the validation cohort prior to vaccination to test their capability of 1092 
discriminating vaccine responders.  1093 
There were no differences in IFNγ (p=0.68), IL-1β (p<0.99), or TNFα (p<0.99) between 1094 
HR and LR within the validation cohort (Fig. 6A). When comparing HR and LR within the 1095 
validation cohort, there was also no difference in either birth weight (p=0.58) or weaning weight 1096 
(p=0.74) (Fig. 6B). Similar to the cytokine observations, this may indicate that as the vaccine 1097 
responsiveness phenotype becomes less extreme, physiological differences in body weight 1098 
between vaccine responders are less apparent. 1099 



















































Figure 6: Plasma cytokines at Day 0 and body weight of the validation cohort do not differ 1102 
between high and low responders within the validation cohort. A. Median plasma cytokine 1103 
concentrations of IFNγ, IL-1β, and TNFα of high (HR; n=4; empty circles) and low (LR; n=4; 1104 
filled circles) within the validation cohort prior to vaccination. B. Median body weight of HR 1105 
(empty circles) and LR (filled circles) at birth and weaning (24-days of age). P-values were 1106 
determined using a Mann-Whitney U-Test. 1107 




3.2.3 Validation of Phosphorylation Biomarkers  1109 
To validate the robustness of the vaccine responsiveness phosphorylation biomarkers 1110 
identified in the discovery cohort, the capability of the biomarker phosphorylation events to cluster 1111 
HR and LR kinome profiles was tested using PCA. Subsequently, a comparative analysis was 1112 
conducted to determine if individual biomarker phosphorylation events showed consistent 1113 
phosphorylation patterns between HR and LR of the validation cohort as was observed in the 1114 
discovery cohort.  1115 
3.2.3.1 Validation of Phosphorylation Biomarkers on Day 0 1116 
PCA of HR and LR within the validation cohort on Day 0 using the untargeted, 282-peptide 1117 
kinome profile did not clearly separate kinome profiles based on vaccine responsiveness 1118 
phenotype (Fig. 7A). Then, piglets within the validation cohort were given new IDs to blind 1119 
vaccine response phenotypes, and only the phosphorylation intensities of the 10 phosphorylation 1120 
events determined from the discovery cohort were used for PCA. The cluster analysis using the 10 1121 
phosphorylation biomarkers alone suggests that PC1 (52%) reduces the inter-group overlap 1122 
between HR and LR within the validation cohort compared to the untargeted kinome profile (Fig. 1123 
7B). Together, these cluster analyses suggest that a signature of 10 biomarker phosphorylation 1124 
events better separates HR and LR phenotypes than the complete array of phosphorylation events. 1125 
Next, phosphorylation intensities of the 10 biomarker phosphorylation events between the 1126 
discovery HR and LR were quantified within the validation cohort. This analysis revealed that 1127 
multiple phosphorylation biomarkers observed in the discovery cohort were consistently (similar 1128 
direction of change) differentially phosphorylated between HR and LR within the validation 1129 
cohort. (Fig. 7C). Differential phosphorylation events of peptide targets such as STMN1_S15, 1130 
TRAF6_Y353, and PPP2CA_T304 were consistently differentially phosphorylated (p=0.029) in 1131 
the discovery cohort. CALM1_Y99 showed a trend (p=0.057) of being differentially 1132 
phosphorylated, while the remaining phosphorylation events did not show a trend (p>0.1) between 1133 
HR and LR in the validation cohort. Altogether, multiple phosphorylation events observed in the 1134 
discovery cohort on Day 0 persist between HR and LR within the validation group, even when 1135 


















































































Figure 7: Biomarker phosphorylation events between high and low responders within the 1138 
discovery and validation cohorts on Day 0. Principal component analysis of the high (HR; n=4; 1139 
green) and low (LR; n=4, orange) responders within the validation cohort using A. 282 peptide 1140 
phosphorylation events represented on the kinome array and B. 10 peptide phosphorylation events 1141 
determined to be differentially phosphorylated between HR and LR within the discovery cohort 1142 
on Day 0. Principle components (PCs)  with the highest variance (%) are shown. Ellipses represent 1143 
95% confidence intervals. C. Phosphorylation intensities of the 10 differentially phosphorylated 1144 
peptides on Day 0 of LR (circles) and HR (squares) within the discovery (filled shape) and 1145 
validation (empty shape) cohorts. The horizontal line represents the group median. P-values in C 1146 
are only shown for comparisons between LR and HR within the validation cohort. P-values were 1147 
determined using the Mann-Whitney U-test. 1148 




3.2.3.2 Validation of Phosphorylation Biomarkers on Day 6 1150 
Similar to the Day 0 analyses, the discriminatory capability of the vaccine response 1151 
biomarkers identified within the discovery cohort on Day 6 was evaluated using PCA and 1152 
comparative analysis. One piglet classified as HR in the validation cohort (“388B”) on Day 0 did 1153 
not have PBMCs collected on Day 6 and was substituted with another HR (“893R”) for subsequent 1154 
Day 6 validation cohort analyses. 1155 
On Day 6, PCA of the validation HR and LR using the 282-peptide kinome profile revealed 1156 
indistinct clustering of HR and LR, suggesting the complete array of peptide phosphorylation 1157 
events cannot differentiate the vaccine responsiveness phenotype (Fig. 8A). As with the Day 0 1158 
analysis, the PCA was repeated using only the 11 biomarker phosphorylation events identified in 1159 
the discovery cohort. Reducing the consideration to the 11 biomarker phosphorylation events on 1160 
Day 6 shows a combination of PC1 (45%) and PC2 (21.7%) can separate HR and LR within the 1161 
validation cohort (Fig. 8B). This improvement from overlapping 95% CIs using the untargeted 1162 
kinome profile to completely distinct 95% CIs using the 11 biomarker phosphorylation events 1163 
supports the conclusion that these biomarkers are associated with the magnitude of vaccine 1164 
responsiveness. 1165 
Comparative analysis of the 11 phosphorylation events identified in the discovery cohort 1166 
revealed consistent differences between HR and LR in the validation cohort (Fig. 8C). 1167 
Specifically, the peptide targets STMN1_S15 and Nuclear factor of activated T-cells, cytoplasmic 1168 
1 (NFATC1)_S245 were differentially phosphorylated (p=0.029), while Kelch-Like ECH-1169 
Associated Protein 1 (KEAP1)_Y293/5, and SYK_Y348 were close to the threshold of a trend 1170 
(p=0.11) for having consistent differential phosphorylation. These 4 phosphorylation events 1171 
demonstrate highly similar patterns of direction and magnitude of change in each cohort. For the 1172 
other biomarker phosphorylation events, there are no significant differences in intensity between 1173 
the HR and LR of the validation cohort, indicating not all phosphorylation events are consistently 1174 














































































Figure 8: Biomarker phosphorylation events between high and low responders within the 1177 
discovery and validation cohorts on Day 6. Principal component analysis of the high (HR; n=4; 1178 
green) and low (LR; n=4, orange) responders within the validation cohort using A. 282 peptides 1179 
phosphorylation events represented on the kinome array and B. 11 peptide phosphorylation events 1180 
determined to be differentially phosphorylated between HR and LR within the discovery cohort 1181 
on Day 6. Principle components (PCs) with the highest variance (%) are shown. Ellipses represent 1182 
95% confidence intervals. C. Phosphorylation intensities of the 11 differentially phosphorylated 1183 
peptides on Day 6 of LR (circles) and HR (squares) within the discovery (filled shape) and 1184 
validation (empty shape) cohorts. The horizontal line represents the group median. P-values in C 1185 
are only shown for comparisons between LR and HR within the validation cohort. P-values were 1186 
determined using the Mann-Whitney U-test. 1187 




3.2.4 Conclusions to Section 3.2 1189 
Using an independent subset of high and low vaccine responders, phosphorylation events 1190 
had greater discriminatory capabilities than physiological factors such as circulating plasma 1191 
cytokine concentrations or birthweight, at least within this trial population of piglets. Multiple 1192 
differential phosphorylation events found in the discovery cohort were also differentially 1193 
phosphorylated in the validation cohort; these phosphorylation events improved cluster separation 1194 
of HR and LR compared to an untargeted kinome profile. HR and LR within the validation cohort 1195 
did not reveal differences in plasma cytokines or body weight, suggesting that phosphorylation 1196 
biomarkers better discern vaccine responsiveness than these physiological markers. Following 1197 
these studies, a second vaccine trial was initiated to again evaluate the use of plasma cytokines and 1198 
body weight as biomarkers of vaccine responsiveness and explore the dynamics of circulating 1199 
cytokines and piglet growth prior to vaccination. 1200 
 1201 
3.3 Validating Plasma Cytokine and Body weight Biomarkers in a Second Trial 1202 
A second vaccination trial (“Trial 2020”) was modelled after the first vaccine trial (“Trial 1203 
2015”) to test the hypothesis that plasma cytokines and body weight are associated with vaccine 1204 
responsiveness. Piglets (n=67; 30 female, 37 male) born from multiple litters (n=6 litters; 8-14 1205 
piglets/litter) were vaccinated (RespiSure-One) at 28-days of age (Day 0) and given a booster at 1206 
52-days of age. M. hyopneumoniae-specific serum IgG titers were quantified prior to vaccination 1207 
and at 63-days of age (Day 35) using the commercial IDEXX M. hyo Ab ELISA (IDEXX 1208 
Laboratories, Inc.). All piglets within this trial (n=67) were seronegative (S/P<0.3) for M. 1209 
hyopneumoniae-specific serum IgG prior to vaccination and all piglets were seroconverted 1210 
(S/P>0.4) on Day 35.   1211 
3.3.1 Variability of Vaccine Responses between Trials 1212 
To quantify vaccine-induced antibody responses, post-vaccination serum was serially 1213 
diluted 5-fold, and endpoint serum IgG titers were calculated. There was an 8-fold difference 1214 
between the highest and lowest Log2 serum IgG titers (titer range = 10.0 –13.2; median (95% CI) 1215 
= 11.8 (11.0 – 12.1)). In contrast with piglets within the first trial (titer range = 5.85 – 13.67; 1216 
median (95% CI) = 9.96 (9.65 – 10.2)) described in Section 3.1, piglets within the second trial had 1217 




no sex-dependent (p=0.13; Mann-Whitney U-test) effect on post-vaccination serum IgG titers. 1219 
Serum samples from piglets within the second trial were collected in two batches (3 litters/batch) 1220 
on different experimental days, and no batch-dependent (p=0.35; Mann-Whitney U-test) effect 1221 
was observed. Altogether, piglets from the second trial had higher serum IgG titers with less 1222 
variation than piglets from the first trial.  1223 
Similar to the first trial, piglets from the second trial representing the 90th percentile and 1224 
10th percentile of serum IgG titers on Day 35 were stratified into HR (n=6) and LR (n=6), 1225 
respectively, to establish cohorts of piglets with the most extreme differences in serum IgG titers. 1226 
When comparing the post-vaccination serum IgG titers of HR and LR between trials, there was no 1227 
difference (p=0.89) between HR of the second (mean ± SD = 12.9 ± 0.18) and first (mean ± SD = 1228 
12.9 ± 0.64) trials (Fig. 9B). In contrast, all LR within the second trial were seropositive (S/P>0.4) 1229 
and had significantly higher (p<0.001) post-vaccination serum IgG titers (mean ± SD = 10.3 ± 1230 
0.11) than the seronegative LRs within the first trial (mean ± SD = 5.85 ± 0.71) (Fig. 9B). Thus, 1231 
the LR within the second trial did not phenotypically represent seronegative non-responders. LR 1232 
from the second trial more appropriately represent seropositive vaccine responders with lower 1233 
serum IgG titers than the HR. However, since LR from the second trial had statistically lower 1234 
serum IgG titers than the HR from the second trial, they were used to test the previously identified 1235 
associations between vaccine-induced antibody responses and either plasma cytokines or birth 1236 
weight.  1237 


















































































Figure 9: Mycoplasma hyopneumoniae-specific serum IgG titers of piglets from the first 1240 
(Trial 2015) and second (Trial 2020) trials 11-days following booster RespiSure-One 1241 
vaccination. A. Median (±95% confidence interval) M. hyopneumoniae–specific serum IgG titers 1242 
of piglets from the first (n=117; open circles) and second (n=67; solid circles) trials. Differences 1243 
were determined using a 2-sample Kolmogorov–Smirnov test. B. Mean M. hyopneumoniae–1244 
specific serum IgG titers of the high (HR) and low (LR) responders within the first (n=6/cohort; 1245 
open circles) and second (n=6/cohort; closed circles) trials. The horizontal bar represents the group 1246 
mean. Dashed and dotted lines represent the threshold for seropositive and seronegative cutoffs, 1247 
respectively. Differences were determined using a two-tailed, unpaired Student’s t-test with 1248 
Welch’s correction.  1249 




3.3.2 Plasma Cytokines and Vaccine Responsiveness in the Second Trial  1251 
Associations between plasma cytokines and vaccine-induced antibody responses were 1252 
identified in the first trial. To test the relationship between Day 0 plasma cytokine concentrations 1253 
and vaccine-induced antibody responses further, correlation and comparative analyses were 1254 
conducted on piglets from the second trial. Here, Day 0 plasma IFNγ levels prior to vaccination 1255 
did not reveal a significant (ρ=0.10, p-value=0.41) correlation with Day 35 serum IgG titers among 1256 
all piglets (n=67) (Fig. 10A). Similarly, Day 0 plasma IL-1β levels prior to vaccination and Day 1257 
35 serum IgG titers were not significantly correlated (ρ=0.13, p-value=0.28) (Fig. 10B). Limiting 1258 
the analysis to only the HR (n=6) and LR (n=6) within the second trial revealed no rank-sum 1259 
differences in Day 0 plasma IFNγ (p=0.34) between HR and LR and a trend towards higher plasma 1260 
IL-1β (p=0.12) in HR than LR (Fig. 10C). Overall, no associations between pre-vaccination 1261 
plasma cytokine concentrations and post-vaccination vaccine-induced serum IgG titers were 1262 
identified in the second trial. There were no significant differences (p=0.81) in post-vaccination 1263 
serum IgG titers among litters (Fig. 10D). While plasma IFNγ and IL-1β concentrations at the time 1264 
of vaccination were associated with vaccine responsiveness within HR and LR from the first trial, 1265 
these data suggest the elevated plasma cytokine concentrations do not always correlate with the 1266 







































































































































































Figure 10: Plasma cytokine concentrations do not correlate with Mycoplasma 1269 
hyopneumoniae-specific IgG titers in the second trial. A. Correlation analysis of post-1270 
vaccination M. hyopneumoniae-specific serum IgG titers with Day 0 plasma IFNγ and B. Day 0 1271 
plasma IL-1β concentrations within piglets of the second trial (n=67). Best-fit lines were 1272 
determined using Spearman Rank Correlation. C. Mean Day 0 plasma concentrations of IFNγ 1273 
(circles) and IL-1β (squares) in low (LR; n=6; solid symbol) and (HR; n=6; open symbol) within 1274 
the second trial. Differences were determined using a Student’s t-test with Welch’s correction. D. 1275 
Mean (±SEM) Log2 M. hyopneumoniae-specific serum IgG titer of piglets from the second trial 1276 
grouped by the factor “Litter”. Differences were determined using a one-way ANOVA. 1277 




3.3.3 Dynamic Concentrations of Plasma Cytokines  1279 
The first trial revealed that piglets with lower vaccine-induced antibody responses had 1280 
elevated plasma cytokines, specifically IFNγ and IL-1β, prior to vaccination compared to age-1281 
matched piglets with higher vaccine-induced antibody responses. However, these plasma 1282 
cytokines were measured only at the time of vaccination (28-days of age; Day 0), and it is unknown 1283 
if differences in cytokine concentrations persisted at different time points. Though plasma 1284 
cytokines were not associated with vaccine responsiveness in piglets from the second trial, the 1285 
opportunity remained to investigate additional time points to evaluate the stability of plasma 1286 
cytokines in young piglets for future reference. 1287 
3.3.3.1 Temporal Variability of Plasma Cytokine Concentrations in Piglets 1288 
Plasma IFNγ and IL-1β were measured at 7-day intervals beginning at birth to 28-days of 1289 
age (primary vaccination) as well as at 63-days of age to determine the temporal stability of 1290 
cytokine biomarkers prior to and following vaccination. Within the second trial, there was a 1291 
significant time-dependent effect (p<0.001) on plasma IFNγ and IL-1β concentrations within all 1292 
piglets. Plasma IFNγ concentration was highest at birth and decreased significantly (p<0.001) by 1293 
14-days of age. Piglets had the lowest concentrations of plasma IFNγ at 63-days of age (p<0.001) 1294 
(Fig. 11A). In contrast, IL-1β did not show age-dependent changes between birth and 28-days of 1295 
age. However, IL-1β concentrations were significantly lower (p<0.001) at 63-days of age than at 1296 
birth (Fig. 11B). Temporal variation in plasma cytokines following birth could limit the use of 1297 
plasma IFNγ or IL-1β as vaccine response biomarkers if they do not consistently associate with 1298 
vaccine-induced immunity. 1299 
3.3.3.2 Litter-specific differences in Plasma Cytokines 1300 
Piglets were grouped within litters and a two-way mixed-effects ANOVA with Tukey’s 1301 
multiple comparisons was conducted using the factors “Litter” and “Time” to account for litter-1302 
dependent variability in plasma IFNγ and IL-1β concentrations among litters at each time point. 1303 
There was a significant (p<0.001) interaction between “Litter” and “Time” for mean plasma IFNγ 1304 
concentrations. One litter, “653-3E” (n=11), had consistently higher levels of plasma IFNγ than 1305 
the other 5 litters at 0-, 7-, 14-, 21- (p<0.001), and 28-days of age (p<0.01) (Fig. 11C). This 1306 
difference in plasma IFNγ levels between Litter 653-3E and the other 5 litters waned and was not 1307 




as Litter 720-1E (n=12) had higher (p<0.05) plasma IFNγ than 3 other litters at birth, but these 1309 
differences were not consistent at subsequent time points. Differences in plasma IFNγ 1310 
concentration among litters were not observed at 63-days of age except for few individual 1311 
differences that were not consistent with other time points. All litters had lower (p<0.05) plasma 1312 
IFNγ at 63-days of age than birth, except for Litter 269-2F (n=8), which only showed a trend 1313 
towards (p=0.07) lower concentrations (Fig. 11C). 1314 
A two-way mixed-effects ANOVA using the factors “Litter” and “Time” was conducted 1315 
to identify differences in mean plasma IL-1β concentrations among litters within the second trial. 1316 
There was a significant (p<0.001) interaction between “Litter” and “Time” on IL-1β 1317 
concentrations. A comparison among litters revealed Litter 653-3E had significantly higher plasma 1318 
IL-1β concentrations than the other 5 litters at birth (p<0.005), four litters at 7- and 14-days of age 1319 
(p<0.005), and four litters at 21- and 28-days of age (p<0.05) (Fig. 11D). At 63-days of age, all 1320 
litters had lower (p<0.01) plasma IL-1β concentrations than at birth. Four litters had lower 1321 
(p<0.05) plasma IL-1β concentrations at 63-days of age than all other time points. Litter 423-3E 1322 
(n=12) had significantly lower (p<0.005) mean plasma IL-1β concentration than three other litters 1323 
at 63-days of age, but this difference was not observed at other time points.  1324 
Routine monitoring and clinical assessment of piglets throughout the current study did not 1325 
identify clinical signs of infection, physical injury, or trauma, supporting the conclusion that illness 1326 
did not cause the elevated plasma IFNγ and IL-1β, specifically within Litter 653-3E. To determine 1327 
if this difference in litter-specific plasma cytokines was related to the number of times a sow had 1328 
given birth, we investigated the parity of sows and the level of plasma cytokines in piglets at birth. 1329 
Sows used in this study had a parity of 0-3, and no relationship between parity and cytokine 1330 
concentrations was found. Observing a litter (Litter 653-3E) with elevated plasma cytokines 1331 
compared to other litters with unimpaired vaccine-induced serum IgG titers showed that high 1332 
cytokine concentrations at the time of vaccination did not always classify piglets as low vaccine 1333 
responders. However, the elevated IFNγ and IL-1β within this biologically-related litter from the 1334 
second trial may have different roles than the individual LR piglets from the first trial. Data from 1335 
the two trials suggest that the plasma cytokines biomarkers may be situationally dependent for 1336 



































































































































Figure 11: Plasma cytokine concentrations of piglets within the second trial from birth to 63-1339 
days of age at weekly intervals. A. Mean (±SEM) plasma interferon-gamma (IFNγ) and B. 1340 
interleukin 1-beta (IL-1β) concentrations measured weekly from piglets within the second trial 1341 
(n=67) from 0-days of age until 28-days of age and at 63-days of age. Differences were determined 1342 
using a Kruskal-Wallis one-way ANOVA with Dunn’s multiple comparisons. C. Mean (±SEM) 1343 
plasma IFNγ and D. IL-1β concentrations of piglets from the second trial were quantified weekly 1344 
from 0-days to 28-days of age and at 63-days of age grouped by the factor “Litter” (n=8-14/litter). 1345 
Differences were determined using a two-way mixed-effects ANOVA with Tukey’s multiple 1346 
comparisons. Asterisks designate differences in mean cytokine concentration among all litters. 1347 
Only P-values representing the differences across all multiple comparisons among litters are 1348 
shown. n.s.p>0.05, *p<0.05; **p<0.01; ***p<0.005; ****p<0.001. 1349 




3.3.4 Birth weight and Vaccine Responsiveness in the Second Trial 1351 
As the first trial revealed a positive correlation between piglet body weight and vaccine-1352 
induced antibody responses, the hypothesis that there were associations between body weight and 1353 
serum IgG titers was tested further in the second trial. A Pearson correlation analysis was 1354 
conducted to determine if body weight and average daily gain (ADG) were associated with 1355 
vaccine-induced antibody responses. Piglets from the second trial had positive (r>0.4) Pearson 1356 
correlations (p<0.05) among body weights at 0- (birth), 7-, 14-, 21-, 24- (weaning), and 63-days 1357 
of age (Fig. 12A). Additionally, piglets had positive correlations between all body weights and 1358 
their ADG from 0- to 24-days of age (birth to weaning) and from 0- to 63-days of age (birth to end 1359 
of the trial) (Fig. 12A). There were no significant correlations (p>0.10) between Day 35 serum 1360 
IgG titers and body weights or ADGs of piglets within the second trial (Fig. 12A). In the first trial, 1361 
LR had lower birth weight and lower weaning weight than HR, but there was no difference in body 1362 
weight at 63-days of age (Fig. 12C). In the second trial, there was no difference in body weight 1363 
between HR and LR at birth (p=0.91) or the end of the trial (p=0.95) (Fig. 12B). While there was 1364 
a trend of LR having a higher weaning weight than HR (p=0.097), this trend was not consistent 1365 
with other time points (Fig. 12B).  1366 
When comparing HR and LR between trials, there are no differences in body weights 1367 
between HR of the first and second trials. Though LRs from the second trial have higher (p=0.033) 1368 
body weight than LRs from the first trial at weaning, this difference is not observed at other time 1369 
points (Fig. 12C). To further test if birth weight was associated with vaccine responsiveness, post-1370 
vaccination serum IgG titers between the highest (n=6) and lowest (n=6) birth weight piglets were 1371 
analyzed. This analysis revealed no difference (p=0.48) in serum IgG titers between the largest 1372 
and smallest piglets at birth (Fig. 12D). Altogether, there were no significant associations between 1373 

































































































































Figure 12: High and low vaccine responders in the second vaccine trial do not differ 1376 
significantly in body weight. A. Pearson correlation matrix of body weights at 0- (BW_0), 7-, 14-1377 
, 21-, 24-, and 63-days of age, pre-weaning average daily gain (ADG_0_24), total average daily 1378 
gain (ADG_0_63) and Log2 M. hyopneumoniae-specific serum IgG titer (Log2Titer_63) of piglets 1379 
from the second trial (n=67). Scale represents Pearson correlation coefficients between 1380 
comparisons. Crosses designate insignificant (p>0.05) Pearson correlations. B. Mean (±SEM) 1381 
body weight (kg) of low (LR; n=6; filled circles) and high (HR; n=6; empty circles) at birth, 1382 
weaning, and end of trial time points experiment. C. Mean (±SEM) body weight (kg) of LR (n=6) 1383 
and HR (n=6) within the second and first trials at birth, weaning, and end of trial time points. D. 1384 
Mean (±SEM) Log2 M. hyopneumoniae-specific serum IgG titer of animals with the lowest (n=6) 1385 
and highest (n=6) weight at birth. P-values were determined using a two-tailed, unpaired Student’s 1386 
t-test with Welch’s correction.  1387 




3.3.5 Conclusions to Section 3.3 1389 
The second vaccine trial provided multiple insights on using physiological markers as biomarkers 1390 
of vaccine responsiveness. First, plasma cytokines such as IFNγ and IL-1β show time-dependent 1391 
and litter-dependent effects in young piglets. Thus, a cytokine biomarker may need to account for 1392 
these temporal changes. Second, piglets with the highest plasma cytokines concentrations at the 1393 
time of vaccination did not have impaired vaccine responses. This suggests that while elevated 1394 
plasma cytokines can be associated with impaired vaccine responses, they may not always be 1395 
indicative of low vaccine responders. This is consistent with literature demonstrating that cytokine 1396 
profiling of low vaccine-induced antibody responders does not always reveal correlations with 1397 
IFNγ and IL-1β (Fourati et al., 2016; Qiu et al., 2018). As well, piglets with the lowest birth 1398 
weights did not have lower vaccine responses, which was hypothesized as a risk factor for impaired 1399 
immune responsiveness in humans and piglets (Bæk et al., 2020; McDade et al., 2001; Milligan 1400 
et al., 2002a). Since LR piglets selected in the first trial were seronegative and LR piglets selected 1401 
in second trial were seropositive, the inconsistencies between vaccine trials could result from the 1402 
definition of “low responder”. Further analysis is needed to verify whether seronegative low 1403 
responders have elevated plasma cytokines and lower birth weight compared to seropositive 1404 
responders. Together, data from the second trial provides further understanding of the immune-1405 
environment of piglets prior to vaccination and reveals situational-dependencies for utilizing 1406 
physiological vaccine responsiveness biomarkers. 1407 




4. DISCUSSION  1409 
 1410 
Vaccination remains one of the most effective methods for minimizing disease outbreaks 1411 
and reducing infectious disease incidence in human and animal populations. Antibiotics are 1412 
another tool for managing infectious diseases caused by bacterial infection, although antibiotic use 1413 
(and misuse) can contribute to the rise of antibiotic resistance in pathogens (Potter et al., 2008). 1414 
Other strategies such as genetic selection could facilitate the development of a healthier population 1415 
by selectively breeding for livestock with more protective immune responses and increased disease 1416 
resistance (Mallard et al., 2015). However, identifying highly heritable traits that correlate with 1417 
disease resistance and other immune traits requires further optimization (Samorè and Fontanesi, 1418 
2016). One potential limitation to the effectiveness of vaccination is that variations in vaccine 1419 
immunogenicity among individuals can result in unresponsive, susceptible individuals within the 1420 
population. Low vaccine responders have the potential for contracting and transmitting disease 1421 
agents, which compromises the protection afforded to the population by herd immunity. 1422 
Identifying effective biomarkers that predict vaccine-induced immune responses is one potential 1423 
solution to this problem. This thesis demonstrates complementary explorations for discovering and 1424 
validating potential biomarkers of vaccine responsiveness.  1425 
4.1 Pre-vaccination Phosphorylation Biomarkers of Vaccine Responsiveness 1426 
Pre-vaccination biomarkers of vaccine responsiveness are beneficial in two ways: their 1427 
detection could help identify low responders in a population, and they may provide insight into the 1428 
molecular mechanisms of the vaccine responsiveness phenotype. Therefore, a phenotype-first 1429 
approach identified high (HR) and low (LR) vaccine responders, and kinome analysis was 1430 
conducted on PBMCs collected from piglets prior to, and following, vaccination to identify the 1431 
signaling events associated with vaccine-induced antibody responses. Kinome analysis revealed 1432 
numerous differences in phosphorylation prior to vaccination when comparing HR and LR within 1433 
a discovery cohort. Differential phosphorylation of peptide targets representing proteins like 1434 
BLNK, TRAF6, IL6ST, and the others (Table 1) suggest differential signaling events within 1435 
PBMCs might influence processes involved in vaccine-induced antibody responses.  1436 
In an independent analysis that used the same vaccine responders from the first trial 1437 
described in Section 3.1, RNA-seq was conducted on PBMCs collected from high and low 1438 




found no differences in gene expression between HR (n=15) and LR (n=15) on Day 0. While 1440 
Munyaka et al. (2019) used a larger sample size (n=15/phenotype) than the kinome analysis 1441 
(n=6/phenotype), their results suggested that HR and LR had identical transcriptional processes at 1442 
the time of vaccination, which contrasts with the kinome analysis of the same subjects. These 1443 
discrepancies could reflect different levels of sensitivity with each technology or the ability of the 1444 
kinome analysis to identify phenotypic differences that do not require changes in gene expression. 1445 
However, other transcriptional analyses have identified pre-vaccination differences in gene 1446 
expression that correlate with vaccine-induced responses in piglets. Functional enrichment 1447 
analysis of the gene expression events within PBMCs collected from 28-day old piglets prior to 1448 
M. hyopneumoniae vaccination found processes and functions such as cell junction and adhesion, 1449 
the extracellular matrix, signal transduction, and inflammation, were associated with vaccine-1450 
specific responses at 118-days post-vaccination (Blanc et al., 2021). Future vaccine responsiveness 1451 
investigations utilizing genomic or transcriptomic approaches might gain complementing 1452 
perspectives on the immune environment by incorporating systems analyses of protein post-1453 
translation modifications. 1454 
A previous kinome investigation conducted on PBMCs collected from humans and pigs 1455 
demonstrated that individuals have temporally stable phosphorylation patterns that were unique to 1456 
each individual, suggesting that individuals possess consistent signaling events independent of 1457 
immune stimulation (Trost et al., 2013b). The hypothesis that the baseline state of the immune 1458 
system affects immune responsiveness has been an area of recent exploration. Pre-vaccination 1459 
gene expression of apoptotic genes were positively correlated with vaccine responses in a previous 1460 
transcriptional analysis of humans vaccinated with an influenza virus vaccine, illuminating 1461 
potential baseline gene expression markers of vaccine responses (Furman et al., 2013). Tsang et 1462 
al. (2020) proposed that further understanding of an individual’s baseline state can direct new 1463 
methods of vaccine administration that modulate the immune system prior to vaccine delivery for 1464 
improved responsiveness (Tsang et al., 2020). However, this study uses young (28-day old) piglets 1465 
undergoing developmental changes similar to neonates in other species, such as changes in blood 1466 
leukocyte populations, cytokine production, and the transition from passive to active immunity 1467 
(Chase et al., 2008; Nguyen et al., 2007; Talker et al., 2013). Therefore, the “baseline” immune 1468 
state at Day 0 might not model the baseline states described in studies investigating mature, human 1469 




al., 2014). More accurately, this work revealed novel phosphorylation events when comparing 1471 
high and low vaccine responders, suggesting that differences in cellular activity at the time of 1472 
vaccination can influence vaccine-induced antibody responses.  1473 
4.2 Post-vaccination Phosphorylation Markers of Vaccine Responsiveness  1474 
The molecular events of vaccine responsiveness have been primarily characterized through 1475 
genomic, transcriptomic, cytometric, and microbiomic analyses to characterize the biological 1476 
mechanisms associated with vaccine responses. In this study, kinome analysis of PBMCs collected 1477 
from HR and LR at 2- and 6-days post-vaccination revealed a panel of 11 differential 1478 
phosphorylation events at 6-days post-vaccination, yet there were no differences at 2-days post-1479 
vaccination. The inability to detect differences between HR and LR at a particular time point may 1480 
result from strict statistical criteria for detecting differential phosphorylation events or could 1481 
accurately reflect kinase signaling changes within PBMCs following vaccination. Also, the kinome 1482 
array used in these analyses consisted of 282 phosphorylation events representing 148 proteins, a 1483 
small fraction of the complete porcine proteome. The kinome array did not represent all possible 1484 
protein targets involved in the innate immune signaling events 2-days post-vaccination. The most 1485 
significant number of temporal phosphorylation changes within LR occurred between 2- and 6-1486 
days post-vaccination, suggesting that active processes occurring within the PBMCs may not have 1487 
been captured on Day 2, but occurred between these two time points.  1488 
Compared to the transcriptional analysis by Munyaka et al. (2019), there were no 1489 
differential gene expression events between high and low vaccine responders at either 2- or 6-days 1490 
post-vaccination. However, a discrimination analysis was capable of partially discriminating high 1491 
and low responders using gene expression events at 2-days post-vaccination only. Proteins 1492 
encoded by the genes contributing to the distinction of high and low responders on Day 2 were not 1493 
represented on the kinome array used in the analyses reported in this thesis (Munyaka et al., 2019). 1494 
Therefore, it was not possible to directly compare the RNAseq data with the biomarkers identified 1495 
in the kinome study, emphasizing differences in the scope of these two analyses. Ultimately, HR 1496 
and LR selected in the first trial only had detectable phosphorylation differences, but no 1497 
transcriptional differences, at 6-days post-vaccination. The kinetics of kinase signaling and gene 1498 
expression likely influence their detection; signaling cascades can activate and decay within 1499 




et al., 2010; Lemmon et al., 2016). Paired with the regulation of signal cascades and mRNA 1501 
abundance, finding kinomic or transcriptomic changes within HR and LR could be highly 1502 
dependent on the time of sample collection (Rauch et al., 2011).  1503 
Independent studies have observed transcriptomic changes that associate with antibody 1504 
responses in other vaccination trials and at other post-vaccination time points within piglets. For 1505 
example, Matthijis et al. (2019) demonstrated that gene expression of inflammatory and antigen 1506 
presentation networks occur within PBMCs of piglets vaccinated with experimental M. 1507 
hyopneumoniae vaccine formulations as early as 24-hours post-vaccination (Matthijs et al., 2019). 1508 
Furthermore, although there were no differences in gene expression prior to vaccination, high and 1509 
low antibody responders vaccinated against tetanus toxoid showed differences in gene expression 1510 
between 2-4 weeks post-vaccination (Adler et al., 2015). Together, these studies show that high 1511 
and low vaccine responder piglets can exhibit unique molecular changes at the transcriptomic level 1512 
that correlate with vaccine outcomes. The post-vaccination kinome data provides additional 1513 
evidence of molecular changes within PBMCs following vaccination.  1514 
4.3 Validation of Phosphorylation Biomarkers 1515 
Kinome analysis was performed on HR and LR representing the extremes of vaccine 1516 
responses, namely, subjects within the 80th and 20th percentile of vaccine-induced antibody 1517 
responses, respectively. One potential study design would utilize all 10 HR and 10 LR in a single 1518 
discovery cohort to discover differential phosphorylation events. While such a study design would 1519 
increase the statistical power to identify positive results with high confidence, it would lack the 1520 
ability to validate any discovered phosphorylation events. Therefore, the data was split into a 1521 
discovery cohort with 60% of vaccine responders (6 HR and 6 LR) and a validation cohort with 1522 
the remaining 40% of vaccine responders (4 HR and 4 LR). Piglets from the validation cohort 1523 
represented vaccine responders of less extreme phenotype compared to the discovery cohort. 1524 
Among the differential phosphorylation events identified in the discovery cohort, multiple 1525 
phosphorylation events were similarly differentially phosphorylated in the validation cohort. 1526 
Indeed, the small sample size of the validation cohort could result in lower statistical power for 1527 
detecting differences between HR and LR. As well, the difference in magnitude of vaccine 1528 
responses between discovery and validation cohorts may explain the incomplete agreement in 1529 




phosphorylation biomarkers to predict the susceptibility of honeybees to Varroa mite infestation 1531 
(Robertson et al., 2014, 2020). When applying phosphorylation biomarkers discovered in subjects 1532 
of the most extreme phenotype, the phosphorylation biomarkers had markedly less intensity within 1533 
the independent subjects of lesser phenotype.  1534 
A variety of other models used in systems vaccinology studies utilize sophisticated feature 1535 
selection, novel algorithms, independent populations for testing the model, and methods of 1536 
evaluating the model (Gonzalez-Dias et al., 2020). For example, a 10-fold cross-validation method 1537 
was used to develop predictive models for predicting CD8+ T-cell responses to Yellow Fever 1538 
vaccination and humoral responses to influenza vaccination in humans using gene expression data 1539 
(Gaucher et al., 2008; Nakaya et al., 2011). In both studies, multiple independent trials were used 1540 
to discover predictive biomarkers of the vaccine response and validate the sets of biomarkers. In 1541 
comparison to observations reported in this thesis, the validation methods here included a 1542 
comparative analysis of phosphorylation events, the clustering of the independent vaccine 1543 
responders, and replication of the vaccine trial in an independent population to evaluate 1544 
biomarkers. These validation methods might be improved in future trials with larger sample sizes. 1545 
4.4 Comparing Vaccine Responses between Trials 1546 
The two vaccine trials utilizing age-matched piglets exhibited different levels of 1547 
seroconversion and range of antibody responses following vaccination with the same commercial 1548 
vaccine. In the first trial (n=117), there was a 64-fold range in serum IgG titers resulting in both 1549 
seropositive and seronegative piglets. Comparatively, piglets from the second trial (n=67) had less 1550 
variance in serum IgG titers 11-days following booster vaccination than piglets from the first trial; 1551 
only an 8-fold range in serum IgG titers was observed between HR and LR in the second trial. 1552 
Interestingly, all the piglets from the second trial were considered seropositive (S/P<0.4) post-1553 
vaccination, demonstrating highly different distributions in vaccine responsiveness when 1554 
comparing the two vaccine trials. There are several factors to consider when comparing the 1555 
antibody responses of these two trials. 1556 
The first trial consisted of 117 piglets selected from 20 different litters, whereas the second 1557 
trial had almost half the number of piglets (n=67) selected from only 6 different litters. The larger 1558 
sample size in the first trial may have provided a higher probability of encountering vaccine non-1559 




was vaccinated with an inactivated M. hyopneumoniae vaccine (Stellamune; Elanco) at 28-days of 1561 
age. Broad variation of M. hyopneumoniae-specific IgG titers were observed at 21-, 35-, and 118-1562 
days post-vaccination. In agreement with the second vaccine trial described here, Blanc et al. 1563 
(2021) reported almost all pigs to be seropositive (S/P>0.4) 11-days following booster vaccination. 1564 
Only 19 piglets were seronegative (S/P<0.4) at 118-days post-vaccination (Blanc et al., 2021). 1565 
This study provides further evidence that piglets often exhibit variable M. hyopneumoniae-specific 1566 
responses following vaccination, albeit at a later post-vaccination time point than analyzed in the 1567 
first vaccine trial described here. 1568 
Another potential issue is that the two vaccine trials reported in this thesis were conducted 1569 
at different pig production facilities and there was a 5-year interval between studies. Both trials 1570 
used RespiSure-One with Amphigen adjuvant (lot numbers not recorded), and there was no 1571 
evidence that vaccine formulation changed within this timeframe (based on personal 1572 
communication with the Associate Director of Zoetis, USA). The two facilities may have 1573 
environmental differences, different animal handling practices that triggered a stress response, or 1574 
have differences in diet and microbiome composition that could modulate the magnitude of 1575 
antibody responses (de Groot et al., 2001; Tuchscherer et al., 2000). For example, the gut 1576 
microbiota composition of weaned piglets has been found to vary among facilities (Luise et al., 1577 
2021) and may impact humoral responses similar to other studies conducted in mice, humans, and 1578 
pigs (Hagan et al., 2019; Munyaka et al., 2020; Oh et al., 2014). Vaccine failure, a result of spoiled 1579 
vaccine or improper injection, may result in poor vaccine-induced responses. However, this is 1580 
unlikely to have occurred in the first trial because piglets were vaccinated in 4 batches (28-30 1581 
piglets/batch), and each batch contained both seropositive and seronegative vaccine responders. 1582 
Taken together, the two vaccine trials provide novel findings. First, vaccination with 1583 
RespiSure-One can result in variable vaccine-induced antibody responses. Second, the level of 1584 
seroconversion can either be complete, as in the second trial, or insufficient, as in the first trial. 1585 
The implications of this are that the LR subpopulations defined in the first and second trials may 1586 
not be biologically similar. For example, the LR selected for the first vaccine trial were 1587 
seronegative, but the LR selected for the second vaccine trial were seropositive. Thus, the 1588 
biomarkers discovered with piglets from the first trial might not be capable of identifying the LR 1589 




responses than the high responders and were utilized to evaluate the use of the pre-vaccination 1591 
biomarkers in the second trial. 1592 
4.5 Body weight as Biomarkers of Vaccine Responsiveness 1593 
Birth weight is considered a predictor of overall health and survival within piglets; low 1594 
birth weight piglets have a lower growth rate and a greater likelihood of pre-weaning mortality 1595 
(Milligan et al., 2002a; Quiniou et al., 2002). In the first trial, only piglets of average litter weight 1596 
were included to reduce inter-animal variability and ensure survival. Nevertheless, even with this 1597 
selection criteria, LR piglets still had lower body weight at birth and weaning than HR piglets. 1598 
Low birth weight had previously been associated with reduced vaccine outcomes in humans. For 1599 
example, multiple cohorts of persons vaccinated against hepatitis B virus or typhoid vaccines 1600 
demonstrated that reduced serum antibody titer was negatively associated with subject birth weight 1601 
(Han et al., 2012; Moore et al., 2004). In a study of adolescents vaccinated with typhoid vaccine, 1602 
low birth weight was significantly associated with reduced serum typhoid-IgG titers (McDade et 1603 
al., 2001). Incidentally, individuals with reduced serum typhoid-IgG titers also had higher pro-1604 
inflammatory C-reactive protein concentrations in plasma later in life than adolescents with higher 1605 
serum IgG titers (McDade et al., 2011). However, McDade et al. (2001, 2011) studied intra-uterine 1606 
growth restricted individuals. Since intrauterine growth restriction is not strongly correlated with 1607 
birth weight, McDade et al.’s conclusions may not implicate all individuals with low birth weight 1608 
alone (McDade et al., 2001, 2011). This relationship between birth weight and vaccine responses 1609 
is not fully understood, yet it is possible that pre- and postnatal factors have the potential to imprint 1610 
an offspring’s immune system. For example, piglets of lower birth weight receive less colostrum 1611 
after birth than higher birth weight littermates, which has been observed to have consequences on 1612 
a piglet’s developing immune functions (Bæk et al., 2020; Milligan et al., 2002b). Additional 1613 
experiments demonstrating an effect of piglet birth weight on vaccine-induced responses are 1614 
needed to support the biological relevance of these empirical associations. Overall, findings from 1615 
the first vaccination trial led to the hypothesis that low birth weight in piglets could provide a 1616 
simple biomarker of impaired vaccine-induced antibody responses.  1617 
In contrast, the second vaccine trial did not reveal significant associations between either 1618 
growth or weight with antibody responses in HR and LR piglets. To this effect, piglets with the 1619 




weight piglets. Other studies have found that preterm infants and infants with low birth weight do 1621 
not have lower vaccine-induced antibody responses than healthy weight controls (D’angio et al., 1622 
2011; D’Angio et al., 1995; Saari, 2003). These studies suggest that while being a metric of 1623 
development and survival, birth weight does not always predispose individuals to fail to respond 1624 
to vaccination. A recent study found that high antibody responders to M. hyopneumoniae 1625 
vaccination had lower birth weights than low antibody responders, proposing a trade-off between 1626 
immunity and growth in piglets (Blanc et al., 2021). While trial-specific differences (e.g. facility, 1627 
animal handling) could have led to events that impacted vaccine responsiveness in low birth weight 1628 
piglets, the identification of piglets with low birth weight who developed seropositive antibody 1629 
responses in the second vaccine trial highlight the limitations of this biomarker. 1630 
4.6 Cytokines as Biomarkers of Vaccine Responsiveness 1631 
While prediction models have been valuable for identifying low vaccine responders, there 1632 
is an equal necessity to understand the root mechanisms leading to reduced vaccine 1633 
responsiveness. To gain insight into the immune mechanisms differentiating HR and LR, pathway 1634 
analysis was conducted on the differentially phosphorylated peptide targets prior to vaccination, 1635 
which implicated various cytokine signaling pathways. The differential phosphorylation of peptide 1636 
targets that contributed to cytokine pathway enrichment included TRAF6, part of the NF-κB 1637 
signaling pathway, IL6ST, a receptor for the pro-inflammatory IL-6 signaling pathway, and 1638 
STAT4, a transcription factor activated through IL-12 and type-1 interferon-mediated signaling. 1639 
As validation, cytokine analysis of plasma collected from HR and LR within the first vaccine trial 1640 
revealed that LR had greater plasma concentrations of IFNγ and IL-1β than HR. This observation 1641 
supported the hypothesis that pro-inflammatory environments at the time of vaccination can 1642 
negatively impact vaccine-induced antibody responses.  1643 
Systemic, baseline inflammatory processes have been associated with poor vaccine 1644 
responsiveness, which has been best defined in vaccine trials with older humans. For example, 1645 
higher levels of serum TNFα were negatively associated with influenza-specific hemagglutination 1646 
inhibition titers in older humans following influenza virus vaccination (Frasca et al., 2012b). Older 1647 
humans vaccinated with an HBV vaccine had reduced anti-hepatitis B antibody responses, higher 1648 
gene expression of genes involved in type II interferon signaling and complement pathways, and 1649 




2016). Munanja et al. (2014) found that greater frequencies of pro-inflammatory monocytes, 1651 
natural killer cells, and natural killer T-cells were present in circulation prior to vaccination against 1652 
Yellow Fever virus 17D within an African cohort showing impaired humoral and cellular vaccine 1653 
responses in comparison to a Swiss cohort showing unimpaired vaccine responses (Muyanja et al., 1654 
2014). The negative impact of inflammation on vaccine responses has also been observed in 1655 
investigations comparing older and obese mice with younger and healthy-weight mice, 1656 
respectively (Frasca et al., 2014; Park et al., 2014). Altogether, there is strong evidence that pre-1657 
vaccination inflammatory processes can negatively affect the magnitude of vaccine-induced 1658 
antibody responses.  1659 
The second vaccine trial further explored the dynamics of plasma cytokines as robust, 1660 
reliable biomarkers of vaccine responsiveness and revealed that plasma concentrations of IFNγ or 1661 
IL-1β at the time of vaccination were not significantly correlated with vaccine-induced antibody 1662 
responses. There was no difference in plasma IFNγ or IL-1β concentrations between the HR and 1663 
LR within the second trial. While the LR of the second trial did not represent seronegative vaccine 1664 
responders, the presence of seropositive piglets with high IFNγ and IL-1β concentrations at the 1665 
time of vaccination indicates these cytokines have limitations as biomarkers of impaired vaccine 1666 
responses. Indeed, cytokine profiling of vaccine responders has not always revealed correlations 1667 
between pre-vaccination pro-inflammatory cytokines and vaccine-induced antibody responses 1668 
(Fourati et al., 2016; Qiu et al., 2018). Other studies identifying an association between 1669 
inflammatory conditions and vaccine-induced responses were conducted in adult mice and humans 1670 
and may not translate to young, developing piglets.  1671 
However, it is possible that the cytokines detected within LR of the first trial and within 1672 
Litter 653-3E of the second trial had different biological functions. Inflammation can be viewed 1673 
on a spectrum, with basal, homeostatic levels at the lower end and disease-inducing levels at the 1674 
upper end (Chovatiya and Medzhitov, 2014). Elevated pro-inflammatory cytokines can reflect both 1675 
harmful (tissue damage, autoimmunities, necrosis) and beneficial (increased microbial killing, 1676 
response to pathogenic stimuli) inflammatory mechanisms (Bent et al., 2018; Schroder et al., 1677 
2004). Perhaps, high IFNγ, IL-1β, and TNFα within genetically different LR of the first trial 1678 
reflected innate immune-activation associated with poor vaccine-specific humoral responses, 1679 




processes unrelated to vaccine responsiveness. In the future, seronegative low responders are 1681 
necessary to thoroughly test the hypothesis that low responders have greater pro-inflammatory 1682 
cytokines than high responders. If birth weight and plasma cytokines are associated with vaccine-1683 
induced antibody responses, it would suggest that low birth weight or elevated plasma cytokines 1684 
do not immediately predispose animals to impaired vaccine responses. 1685 
4.7 Plasma Cytokines at an Early Age 1686 
Within the second trial, there were litter-specific differences in cytokine concentrations at 1687 
birth. Specifically, there were consistent differences in IFNγ and IL-1β at various time points 1688 
among litters. The most prominent difference was found in a litter of 11 piglets with 2-3x higher 1689 
plasma IFNγ concentrations than the other 5 litters over multiple weeks. This litter of piglets was 1690 
presumably not impacted by an external stimulus, such as infection or injury. Plasma cytokine 1691 
concentrations may have been regulated by a maternal factor, such as genetics or epigenetics, or 1692 
an immunomodulatory environmental factor, such as stress, that specifically affected Litter 653-1693 
3E (Tuchscherer et al., 2000). These differences were not apparent at 63-days of age, suggesting 1694 
that elevated plasma cytokine concentrations reach a baseline level regardless of the concentration 1695 
at birth. Such litter-dependent effects have been observed on other immune parameters in piglets, 1696 
such as PBMC stimulation responses (de Groot et al., 2005). The presence of an entire litter of 1697 
piglets with elevated plasma cytokines, yet unimpaired vaccine responses, was further evidence 1698 
that plasma cytokines are not always associated with vaccine-induced antibody responses.  1699 
The second trial also revealed that plasma IFNγ and IL-1β exhibit temporal changes within 1700 
the first 9 weeks of a piglet’s life; specifically, plasma IFNγ concentrations declined after birth 1701 
and this decline was evident by 14 days of age. Both IFNγ and IL-1β concentrations were lower at 1702 
9 weeks of age compared to concentrations at birth. These results augment previous work by 1703 
Nguyen et al. (2007) who found piglets had decreasing serum concentrations of cytokines such as 1704 
IFNγ, IL-4, and IL-6, within the first 2 weeks of life. Reasons for these decreases are not entirely 1705 
understood but could reflect exogenous absorption of maternal cytokines and colostral cells via 1706 
colostrum from the sow, followed by endogenous production by the piglet as it develops (Nguyen 1707 
et al., 2007; Williams, 1993). Serum IL-1β and IL-6, but not TNFα, concentrations were elevated 1708 
in human infants at 1-day of age and then significantly declined between 1- and 40-days of age 1709 




concentrations in piglets from the second trial further restrict the feasibility of using plasma 1711 
cytokines as a possible biomarker of vaccine responsiveness. 1712 
4.8 Limitations and Future Directions 1713 
This research introduced new avenues for advancing the understanding of vaccine 1714 
responsiveness and for recognizing the limited circumstances of biomarkers of vaccine 1715 
responsiveness. However, these projects also possess limitations in their analysis that must be 1716 
addressed when pursuing future investigations. 1717 
This research uses vaccine-specific antibody responses as the metric of vaccine 1718 
responsiveness. Antibody-mediated immune responses to M. hyopneumoniae are not considered 1719 
protective against infection (Djordjevic et al., 1997). Thus, a vaccine response does not equate to 1720 
protection in this study. Possibly, LR developed strong cell-mediated responses that were not 1721 
measured here yet would be considered a vaccine response in other studies. In the second 1722 
vaccination trial, piglets had varying concentrations of cytokines but this had no significant effect 1723 
on vaccine-specific antibody responses. It remains unknown whether elevated plasma IFNγ or IL-1724 
1β impedes vaccine-specific cell-mediated responses. Therefore, future investigations should 1725 
incorporate cytometric techniques for investigating the heterogeneity of cell populations (ex. 1726 
monocytes, natural killer cells, or naive T- and B-cells) and quantify cellular responses, as in other 1727 
vaccine responsiveness studies (Gaucher et al., 2008; Li et al., 2017). Insight into cell populations 1728 
may also provide context for the results of the kinome analysis. Since the kinome analysis in the 1729 
first vaccination trial was conducted on an assorted population of PBMCs, different proportions of 1730 
immune cell subpopulations may contribute to unique phosphorylation patterns.  1731 
When validating the phosphorylation biomarkers detected in the first vaccination trial, 1732 
cluster analysis and statistical methods were used to evaluate if differential phosphorylated events 1733 
consistently appeared in multiple cohorts. The opportunity remains to utilize more advanced 1734 
techniques to classify ‘vaccine responders’ vs ‘vaccine non-responders’. Others have developed 1735 
pipelines and models for predicting vaccine responsiveness using transcriptomic data, and a similar 1736 
approach can be taken using phosphorylation intensity data (Furman et al., 2013; Lee et al., 2016; 1737 
Nakaya et al., 2011; Querec et al., 2009; Tsang et al., 2014). Predictive capabilities become more 1738 
robust as they are tested on independent populations, which is a vital component of this project; 1739 




population of pigs would be an ideal test of reproducibility. As this kinome analysis focused on 1741 
using vaccine responders with the highest and lowest serum IgG titers as verification, the inclusion 1742 
of average/median vaccine responders may provide additional perspectives on the accuracy of 1743 
these phosphorylation biomarkers (HIPC-CHI Signatures Project Team and Consortium, 2017; 1744 
Thompson-Crispi et al., 2013). HR and LR from the first trial could be utilized to identify 1745 
differential phosphorylation changes between vaccine responders following vaccination if the trial 1746 
included age-matched, unvaccinated controls to account for the developmental immune changes 1747 
independent of vaccination. Lastly, biomarkers must be tested using a different vaccine type, given 1748 
that Li et al. (2014)  found that different human vaccines can  have unique vaccine type-specific 1749 
transcriptional responses (Li et al., 2014). 1750 
The second vaccination trial evaluated the results of the first trial by testing plasma 1751 
cytokines and birthweight as biomarkers for vaccine responsiveness in an independent trial 1752 
population. The second trial provided results that provoked additional questions for understanding 1753 
the immune physiology of neonate piglets. Are there physiological consequences of having greater 1754 
circulating IFNγ at a young age? If so, what role in immunity and development do these cytokines 1755 
play? Do these cytokines represent endogenous production from the piglet? Were cytokines 1756 
transferred from the sow at or before birth? Or was it a combination of endogenous production 1757 
directed by maternal factors? Future directions that investigate these questions should consider 1758 
collecting a comprehensive set of samples from sow and offspring at time points immediately at 1759 
and following birth. With archived cells such as PBMCs collected at a young age, there is an 1760 
opportunity to measure IFNγ-stimulated genes if IFNγ concentrations are high in plasma. In 1761 
addition, blood and colostrum samples collected from the sow may provide insight into the source 1762 
of plasma cytokines in piglets. Finally, a longitudinal analysis of litters from the same sow may 1763 
answer whether litter-specific differences in plasma cytokines represent a maternally-derived 1764 
effect or a consequence of environmental factors. 1765 




5. CONCLUSIONS 1767 
Low and non-responders to vaccination create a challenge to achieving protective 1768 
immunity, both in individuals and the population. The identification and subsequent management 1769 
of low responders could have tremendous benefits for achieving a healthier livestock population 1770 
and improving vaccination programs. This thesis identifies birth weight and elevated plasma 1771 
cytokines at the time of vaccination as biomarkers that were not consistently associated with 1772 
impaired vaccine responses in piglets. Plasma cytokines demonstrate highly variable 1773 
concentrations between subjects and over time, suggesting their use as a stand-alone biomarker 1774 
should be heeded. However, phosphorylation events had increased potential for prediction of 1775 
vaccine responsiveness and may complement other systems approaches by offering a novel 1776 
perspective of the host immune response to vaccination. Together, these data provide insight into 1777 
molecular events that may be associated with vaccine responses within a critical livestock species 1778 
and evaluate the feasibility of using specific physiological factors as biomarkers of vaccine 1779 
responsiveness.   1780 
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